Date of Document: October 31, 2021

CURRICULUM VITAE

Douglas B. Evans MD

Chair, ProfessorDepartment of Surgery

Division of Administration

OFFICE ADDRESS: The Hub for Collaborative Medicine8701 Watertown Plank RoadMilwaukee, WI 53226

EDUCATION: 1974 Diploma, Oliver Ames High School, North Easton, MA1976 - 1977 University of Wales, Swansea, Wales (U.K.)1978 B.S., Bates College, Lewiston, ME1983 M.D., Boston University School of Medicine, Boston, MA

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS: 06/1983 - 06/1984 Internship, Dartmouth-Hitchcock Medical Center (Surgery), Hanover, NH06/1984 - 06/1988 Residency, Dartmouth-Hitchcock Medical Center (General Surgery), Hanover, NH1988 - 1990 Fellowship, M. D. Anderson Cancer Center (Surgical Oncology), University of Texas, Houston,

TX

FACULTY APPOINTMENTS: 1987 - 1988 Instructor in Surgery, Dartmouth Medical School, NH1988 - 1990 Teaching Associate, University of Texas M. D. Anderson Cancer Center, TX1990 - 1995 Assistant Professor of Surgery, University of Texas M. D. Anderson Cancer Center, TX1995 - 2000 Associate Professor of Surgery (with tenure), University of Texas M. D. Anderson Cancer

Center, TX2000 - 2008 Professor of Surgery (with tenure), University of Texas M. D. Anderson Cancer Center, TX2002 - 2008 Hamill Foundation Distinguished Professorship In Honor of Dr. Richard G. Martin, Sr., TX2009 - Present Professor (with tenure) and Chair, Department of Surgery, Medical College of Wisconsin,

Milwaukee, WI2009 - Present Ausman Family Foundation Chair, WI2009 - Present Surgeon-in-Chief, Froedtert Hospital, Milwaukee, WI

SPECIALTY BOARDS AND CERTIFICATION:

Board Certified Issue Date ExpirationNational Board of Medical

Examiners1984 None

American Board of Surgery 1989 None

Certificates Issued By Issue Date ExpirationFellow American College of

Surgeons1993 None

Licensure Number Issue Date Expiration

1 / 41

State of Vermont (inactive) 42-0007162 1984 NoneState of New Hampshire

(inactive)7147 1985 None

State of Texas H5546 1988 NoneState of Wisconsin 52498-20 2008 None

AWARDS AND HONORS: 1985 Resident's Publication Award, Contemporary Surgery1987 Thomas P. Almy Award (outstanding resident educator, Dartmouth Medical School)1995 Outstanding Teacher Award, University of Texas M. D. Anderson Cancer Center, Dept of Surgical

Oncology1998 Faculty Achievement Award in Clinical Research, University of Texas M. D. Anderson Cancer Center1999 American College of Surgeons Traveling Fellowship, (Australia and New Zealand)2003 Outstanding Teacher Award, University of Texas M. D. Anderson Cancer Center, Dept of Surgical

Oncology2014 Excellence in Professionalism Award, Medical College Physicians, MCW2014 Andrew L. Warshaw Master Educator Award, Society for Surgery of the Alimentary Tract Foundation2018 Wisconsin Way Award in Medicine, NewsTalk 1130-WISN and Annex Wealth Management

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES: American Association for Cancer Research American Association of Endocrine Surgeons (Council 2003-2006, Recorder 2005-2008, President-elect

2009-2010, President 2010-2011, Nominating Committee Chair 2014, Council 2010-2014, Ad HocFellowship Accreditation Committee 2015-2018)

American Gastroenterological Association American Hepato-Pancreato-Biliary Association American Society of Clinical Oncology (Program Committee 2000) North American Neuroendocrine Tumor Society (NANETS) (Finance Committee 2015) American Thyroid Association (Program Committee 2010-2013) Pancreas Club Inc. (Board of Directors 2000-2010) Society for Surgery of the Alimentary Tract (Patient Care Committee 2003-2008) Society of Surgical Oncology (Executive Council 1999-2002, Membership Committee 2003-2005, Executive

Council 2004-2007, Nominating Committee 2017 - 2019) Society of University Surgeons American Surgical Association (Flance-Karl Award Committee 2015-2020)

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS: Editorial Board

1998 - 2004 Annals of Surgical Oncology (Section Editor, Hepatic and Pancreatic Tumors)1998 - 2002 AJCC Cancer Staging Manual Sixth Edition (Chair, Digestive System-HPB)1999 - 2020 Surgery2006 - Present American Journal of Surgery2007 - 2009 AJCC Cancer Staging Manual Seventh Edition (Foregut Task Force)2012 - 2016 Annals of Surgical Oncology (Section Editor, Pancreatic Tumors)2017 - Present Journal of Pancreatic Cancer (Associate Editor)

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS: 1998 - 2007 Scientific Advisory Board, Lustgarten Foundation for Pancreatic Cancer Research1999 - 2003 Pancreas Organ Site Committee, American College of Surgeons Oncology Group (ACOSOG)2003 - 2009 Pancreas Disease Site Team, American College of Surgeons Commission on Cancer2003 - Present Medical Advisory Board, Michael Rolfe Pancreatic Cancer Research Foundation2004 - 2008 Medical Advisory Council, Pancreatic Cancer Action Network (PanCAN)2006 - 2007 Steering Committee, NIH/NCI Thyroid FNA State of the Science Conference2007 - 2008 Medullary Thyroid Cancer Guidelines Committee, American Thyroid Association2010 - 2013 Program Committee, American Thyroid Association2011 - Present Sheikh Ahmed Center for Pancreatic Cancer Research Scientific Advisory Board, M. D.

2 / 41

Anderson Cancer Center2012 - 2013 Chair, Research Acceleration Network Grant Scientific Review Committee, Pancreatic Cancer

Action Network (PanCan)-AACR2013 - 2014 Medullary Thyroid Cancer Guidelines, American Thyroid Association2013 - 2014 Chair, Research Acceleration Network Grant Scientific Review Committee, Pancreatic Cancer

Action Network (PanCAN)-AACR2013 - 2016 Scientific Advisory Board (scientific oversight for pancreatic cancer research), Precision

Medicine Research Associates (PMRA)2014 - Present External Advisory Board, City of Hope Comprehensive Cancer Center2016 - Present PanCuRX TRI Mid-Term Review Panel, Ontario Institute for Cancer Research2016 - 2018 Career Development Awards Scientific Review Committee, Pancreatic Cancer Action Network -

American Association for Cancer Research (PanCAN-AACR)2019 - Present National Advisory Council, TGEN (The Translational Genomics Research Institute)

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:

PriorNon-Peer Review

Title: Protocol ID 96-080: Phase I study ofrapid-fractionation external-beamradiation therapy and concomitantGemzar for patients with locally-advanced, nonmetastaticadenocarcinoma of the pancreatic head.

Source: Eli Lilly Co. (Funded Clinical Protocol)Role: P.I.PI: D. EvansDates: 1996 - 1998

Title: 1 RO1 CA75517-01: Basis of

antiangiogenesis therapy in pancreaticcancer.

Source: NIH (External Funding: $478,964)Role: P.I.PI: D. EvansDates: 1997 - 2001

Title: Protocol ID 97-211: (Multi-institutional)

Double-blind, placebo-controlled,randomized phase III study comparingmarimastat to placebo as adjuvant(postoperative) therapy in patients withresectable pancreatic cancer.

Source: British Biotech (Funded ClinicalProtocol)

Role: Co. I.Dates: 1998 - 2000

Title: Protocol ID 98-020: Multi-institutional

phase II study of preoperative rapid-fractionation external-beam radiationtherapy and concomitant Gemzar(gemcitabine) for patients withresectable adenocarcinoma of thepancreatic head.

Source: Eli Lilly Co. (Funded Clinical Protocol)Role: P.I.

3 / 41

PI: D. EvansDates: 1998 - 2001

Title: Protocol GS 99-325: A double-blind

placebo-controlled randomized study ofvapreotide to prevent post-surgicalcomplications in patients undergoingelective pancreatic resection.

Source: DebioPharm (Funded Clinical Protocol)Role: P.I.PI: D. EvansDates: 1999 - 2001

Title: Protocol ID 01-341: Phase II study of

preoperative chemotherapy (gemcitabineand cisplatin) and gemcitabine-basedrapid-fractionation chemoradiation forpatients with resectable adenocarcinomaof the pancreas.

Source: Eli Lilly Co. (Funded Clinical Protocol)Role: P.I.PI: D. EvansDates: 2001 - 2006

Title: 1 P20 CA101936-01: SPORE in

Pancreatic Cancer.Source: NIH (External Funding: $900,000)Role: Co. P.I.Dates: 2003 - 2008

Title: Protocol 2005-0784: Phase II pilot study

of preoperative gemcitabine andbevacizumab-based chemoradiation forpatients with resectable adenocarcinomaof the pancreas.

Source: Genentech (Funded Clinical Protocol)Role: P.I.PI: D. EvansDates: 2005 - 2007

Title: The use of telomerase activity for the

early diagnosis of pancreatic cancer.Source: O.H. Davenport Fund (External Funding:

$15,000)Role: P.I.PI: D. EvansDates: - 1996

INVITED LECTURES/WORKSHOPS/PRESENTATIONS: RegionalPancreatic cancer: diagnosis, combined modality therapy and future studies., Mayo Clinic, Rochester, MN,

04/06/1995Neoadjuvant strategies for pancreatic cancer., Annual Clinical Science Symposium of the Robert H. Lurie

Comprehensive Cancer Center of Northwestern University, Chicago, IL, 09/18/1998The surgical management of pancreatic cancer., The University of Michigan Cancer Center Field of Dreams

Symposium, Dearborn, MI, 09/10/2004

4 / 41

The Challenge of Pancreatic Cancer., Rush University, Chicago, IL, 01/19/2010Treatment sequencing in localized pancreatic cancer., University of Michigan, Ann Arbor, MI, 03/03/2010Pancreatic Cancer: Treatment sequencing in localized disease., University of Wisconsin, Madison, WI,

11/03/2010

NationalLaparoscopic-assisted extracorporeal cholecystojejunostomy., 46th Annual Cancer Symposium of the Society

of Surgical Oncology, Los Angeles, CA, 03/18/1993Pancreatic cancer; the impact of accurate diagnosis and multimodality management (April 26, 1994); Multiple

endocrine neoplasia (April 27, 1994), 41st Annual Symposium of the Society of Air Force ClinicalSurgeons, San Antonio, TX, 04/26/1994 - 04/27/1994

Management of periampullary and pancreatic cancer (July 25, 1994); Multiple endocrine neoplasia (July 26,1994); Adrenal tumors (July 27, 1994), Third Annual General Surgery Update of the Southern MedicalAssociation, Sea Island, GA, 07/25/1994 - 07/27/1994

The genetics of endocrine neoplasia; Early diagnosis of pancreatic cancer., Annual Meeting of the FloridaChapter of the American College of Surgeons, St. Petersburg, FL, 11/12/1994

Adenocarcinoma of the pancreas: the importance of accurate diagnosis and multimodality management.American College of Surgeons 23rd Annual Spring Meeting, Boston, MA., 05/02/1995

Advances in the diagnosis and treatment of pancreatic cancer. Roswell Park Cancer Institute, Buffalo, N.Y.,02/21/1996

Adjuvant and neoadjuvant therapy for pancreatic cancer. 82nd Annual Clinical Congress, American Collegeof Surgeons, San Francisco, CA, 10/08/1996 - 10/10/1996

The importance of accurate preoperative imaging and multimodality therapy in patients with pancreaticcancer. 61st Annual Scientific Meeting of the American College of Gastroenterology, Seattle, WA,10/19/1996

Current and future multimodality treatments for patients with localized pancreatic cancer. Twelfth AnnualNorbert Schnog Memorial Lecture in Pancreatic Cancer, Yale University Cancer Center, New Haven,CT, 01/21/1997

Current treatment of localized pancreatic cancer. Dartmouth Medical School, 02/05/1997New Approaches to pancreatic cancer. Vanderbilt University, 03/10/1997Current status of multidisciplinary clinical research in pancreatic cancer. American Society of Clinical

Oncology, Denver, CO., 05/17/1997 - 05/18/1997Surgical management and follow-up of patients with differentiated thyroid cancer (Oct. 15, 1997);

Laparoscopy in the treatment of pancreatic cancer (Oct. 16 1997)., 83rd Annual Clinical Congress,American College of Surgeons, Chicago, IL, 10/15/1997 - 10/16/1997

Surgery in pancreatic cancer. Advances in solid tumors (Baylor University Medical Center OncologyConference), Captiva Island, Florida, 10/31/1997

Controversies in the management of localized pancreatic cancer (Meet the Professor Program); Technicalexpertise fellowships - pancreas (Education Symposium). 51st Annual Cancer Symposium of theSociety of Surgical Oncology, San Diego, CA, 03/28/1998

Imaging of the liver and pancreas. Twenty-sixth Annual Meeting of the Oklahoma State Radiological Society,Oklahoma City, Okla., 04/25/1998

Adjuvant and neoadjuvant therapy for pancreatic cancer. American College of Surgeons 26th Annual SpringMeeting, Baltimore, MD., 04/27/1998

Pancreatic Cancer: the rationale for current clinical and translational research programs. Twelfth AnnualSurgical Alumni Society Meeting, Scott & White Clinic, Temple, TX, 05/01/1998

Pancreatic cancer: current and future multimodality treatment. American Society of Clinical Oncology, LosAngeles, CA. (Meet the Professor Program), 05/17/1998

Adjuvant and neoadjuvant therapy for pancreatic adenocarcinoma (Oct. 28, 1998); Pancreatic resection:techniques (Oct. 29, 1998). 84th Annual Clinical Congress, American College of Surgeons, Orlando,10/25/1998 - 10/29/1998

Radiation oncology in pancreatic cancer., Radiological Society of North America 84th Scientific Assembly,Chicago, IL, 12/03/1998

Current management of thyroid cancer (March 4, 1999); Neuroendocrine tumors of the pancreas (March 6,1999, Meet the Professor Program). 52nd Annual Cancer Symposium of the Society of SurgicalOncology, Orlando, FL, 03/04/1999 - 03/07/1999

Preoperative chemoradiation and surgery. The Sixth International Conference on Gastrointestinal Oncology,

5 / 41

Williamsburg, Virginia, 10/20/1999Medullary carcinoma of the thyroid and the MEN syndromes. Current concepts in the management of thyroid

cancer (University of Pennsylvania), Philadelphia, PA, 11/05/1999The multimodality management of pancreatic adenocarcinoma. The Steven J. Moses, MD Lectureship, Good

Samaritan Hospital, Cincinnati, OH, 01/14/2000Radical pancreatectomy for adenocarcinoma of the pancreas (Meet the Professor Program); Intraoperative

radiation therapy for pancreatic cancer. 53rd Annual Cancer Symposium of the Society of SurgicalOncology, New Orleans, LA, 03/18/2000

Current management of localized pancreatic cancer. The George Washington University Medical Center,Washington, DC, 03/29/2000

The multimodality treatment of pancreatic adenocarcinoma. The Phillip Lear, MD Lectureship, Long IslandJewish Medical Center, New Hyde Park, NY, 05/04/2000

Adjuvant therapy of resectable pancreatic cancer. American Society of Clinical Oncology, New Orleans, LA.(Invited Discussant), 05/20/2000

Pancreatic cancer and adjuvant therapy: preoperative chemoradiotherapy. 34th Annual Meeting of thePancreas Club, San Diego, CA, 05/21/2000

Pancreatic Cancer: recent developments., Second annual National Oncology Forum, Chicago, IL, 10/15/2000Thyroid carcinoma: optimal extent of resection., 86th Annual Clinical Congress, American College of

Surgeons, Chicago, IL, 10/25/2000Chemoradiation for pancreatic cancer: neoadjuvant therapy is the best strategy. 51st Annual Meeting of the

American Association for the Study of Liver Diseases, Dallas, 10/28/20002000 Special Guest Professor, Advances in Cancer Management for the Surgeon. Harvard Medical School,

Boston, MA., 11/06/2000State-of-the-Art Address: Neoadjuvant therapy for pancreatic cancer. Third Biennial Americas

Hepatopancreatobiliary Congress, sponsored by the AHPBA, Miami Beach, Fla., 02/23/2001Cystic neoplasms of the pancreas. The Annual Emil Jobb Gastroenterology Symposium (Swedish Medical

Center). Seattle, WA, 03/02/2001The surgical management of gastrointestinal endocrine tumors. The 10th Annual Meeting of the American

Association of Clinical Endocrinologists, San Antonio, TX., 05/04/2001Staging of Pancreatic Cancer. Scientific Meeting of the Lustgarten Foundation for Pancreatic Cancer

Research (Johns Hopkins University School of Medicine). Baltimore, MD, 06/14/2001Pancreatic resection techniques. 87th Annual Clinical Congress, American College of Surgeons, New

Orleans, 10/09/2001Extended pancreatectomy for adenocarcinoma of the pancreas (Meet the Professor Program). 55th Annual

Cancer Symposium of the Society of Surgical Oncology, Denver, CO, 03/16/2002Management issues in MEN., The 11th Annual Meeting of the American Association of Clinical

Endocrinologists, Chicago, IL, 05/02/2002(1) Controversies in the treatment of differentiated thyroid cancer;(2) Current management of potentially

resectable pancreatic cancer - both lectures given at UT Southwestern Medical Center, Dallas, TX(Current Topics in General Surgery 2002), 05/11/2002

Is preoperative (neoadjuvant) or postoperative (adjuvant) chemoradiation therapy for pancreaticadenocarcinoma more effective? SSAT 2002 postgraduate course, San Francisco, CA, 05/19/2002

Nonfunctioning islet cell carcinoma of the pancreas (10/7/02, PG15), Preoperative evaluation of pancreaticand periampullary neoplasms (10/7/02, PG16), Adjuvant therapy for respectable pancreatic cancer(10/9/02, GS22). 88th Annual Clinical Congress, American College of Surgeons, San Francisco,10/07/2002 - 10/09/2002

Adenocarcinoma of the pancreas: pretreatment staging. 56th Annual Cancer Symposium of the Society ofSurgical Oncology, Los Angeles, CA, 03/06/2003

Medullary Thyroid Carcinoma. Head and Neck Society of New York, NYC, 03/26/2003Preoperative Therapy for Pancreatic Cancer. Scientific Meeting of the Lustgarten Foundation for Pancreatic

Cancer Research (Dana Farber Cancer Center). Boston, MA, 06/17/2003Controversies in the treatment of differentiated thyroid cancer (10/20/03, PG20), Multiple endocrine

neoplasia type I (10/23/03)., 89th Annual Clinical Congress, American College of Surgeons, Chicago,IL, 10/20/2003 - 10/23/2003

Preoperative staging and the use of vascular resection for pancreatic cancer. Tenth International Conferenceon Gastrointestinal Cancer, Williamsburg, VA, 10/24/2003

Central Neck Dissection. Surgery of the Thyroid and Parathyroid Glands. Harvard Medical School, Boston,

6 / 41

MA, 11/07/2003Adjuvant and neoadjuvant therapy for pancreatic cancer. ASCO/SSO-2004 Gastrointestinal Cancers

Symposium, San Francisco, CA, 01/23/2004Preoperative therapy for localized pancreatic cancer:2004 Gastrointestinal Oncology Conference

(International Society of Gastrointestinal Oncology), Arlington, VA, 07/08/2004Adrenal cortical carcinoma (10/11/04, PG 22). 90th Annual Clinical Congress, American College of

Surgeons, New Orleans, LA, 10/11/2004Adjuvant radiation therapy for pancreatic cancer. ASCO/SSO-2005 Gastrointestinal Cancers Symposium,

Hollywood, Florida, 01/28/2005Multiple Endocrine Neoplasia Syndromes. The Dr. and Mrs. Majid A. Qureshi Lectureship, Good Samaritan

Hospital, Cincinnati, Ohio, 02/25/2005Clinical and laboratory advances in the study of pancreatic cancer. Whitmarsh Lecture, Roger Williams

Medical Center and Brown University. Providence, Rhode Island, 04/22/2005Adjuvant and neoadjuvant therapy for pancreatic cancer., SSAT-2005 postgraduate course, Chicago, IL,

05/15/2005Multimodality management of pancreatic cancer. University of Connecticut, 08/05/2005Neck dissection for thyroid cancer (PG11). 91st Annual Clinical Congress, American College of Surgeons,

San Francisco, 10/18/2005Treatment of localized pancreatic cancer. Oncology World Congress-2005, New York, NY, 11/18/2005Surgical management of pancreatic cancer. Multidisciplinary Symposium on Upper Gastrointestinal

Malignancies, Philadelphia, PA, 12/03/2005Neuroendocrine tumors of the abdomen: Maine Medical Center, 07/06/2006Keynote Address: Surgery of the pancreas: state-of-the-art. University of California, Irvine (Third Annual

Symposium on Interventional Endoscopy), 09/30/2006Adjuvant and neoadjuvant therapy for pancreatic cancer., 92nd Annual Clinical Congress, American College

of Surgeons, Chicago, IL, 10/10/2006Approach to the lateral neck. 77th Annual Meeting of the American Thyroid Association, Phoenix, AZ,

10/14/2006Surgical management of medullary thyroid cancer: The Ohio State University Ernest L. Mazzaferri Thyroid

Cancer Conference. Ohio State University, 11/10/2006Now or later: the best timing for adjuvant therapy in pancreatic cancer. ASCO 2007 Gastrointestinal Cancers

Symposium, Orlando, Florida, 01/20/2007Controversies in the management of localized pancreatic cancer. The George Washington University Medical

Center, Washington, DC, 02/07/2007Adjuvant therapy for pancreatic cancer: recent results and emerging therapies (Meet the Professor Program).

60th Annual Cancer Symposium of the Society of Surgical Oncology, Washington, DC, 03/17/2007State-of-the-Art Address: Management of borderline resectable pancreatic cancer. SAGES & AHPBA 2007,

Las Vegas, NV., 04/22/2007New strategies for borderline resectable pancreatic cancer. DDW / SSAT Combined Symposia, Washington,

DC, 05/22/2007Surgical treatment of pancreatic cancer. Third Annual Oncology World Congress 2007, San Francisco, CA,

09/08/2007David B. Kanner Memorial Lecture (MEN; genotype, phenotype and principles of oncology), Dartmouth

Medical School and the Norris Cotton Cancer Center. Hanover, NH, 11/15/2007Vascular resection as part of pancreaticoduodenectomy for pancreatic cancer. AHPBA consensus conference

on resectable and borderline resectable pancreas cancer. Orlando, Florida, 01/24/2008State of the Art Invited Lecture: Integrated disease-site program development. 2008 Academic Surgical

Congress (ACS/SUS). Huntington Beach, CA, 02/15/2008Prophylactic thyroidectomy in patients with MEN 2 / MEN 2A-associated hyperparathyroidism and

pheochromocytoma. American Thyroid Association National Thyroid Cancer Workshop. Boston, MA,07/11/2008 - 07/12/2008

Pancreatic cancer: what defines resectability and results of surgery. Fourth Annual Oncology World Congress2008, San Francisco, CA, 09/25/2008

The timing of prophylactic thyroidectomy in patients with germ-line RET mutations., 79th Annual Meeting ofthe American Thyroid Association, Chicago, IL, 10/03/2008

Pancreatic Cancer. Arizona Chapter of the American College of Surgeons. Tucson, AZ, 11/01/2008MEN-associated hyperparathyroidism. Surgery of the Thyroid and Parathyroid Glands. Harvard Medical

7 / 41

School. Boston, MA, 11/08/2008Prophylactic surgery for medullary thyroid cancer / MEN2-associated pheochromocytoma and

hyperparathyroidism. Frontiers in Thyroid Cancer: ATA Guidelines in Clinical Practice. Meeting ofthe American Thyroid Association, Miami, FLA, 01/24/2009

Development of a multidisciplinary pancreatic cancer research program. University of Florida. Gainesville,04/22/2009

Neoadjuvant therapy for localized pancreatic cancer. Carolinas Medical Center. Charlotte, NC, 07/09/2009Performance status, CA19-9, CT imaging: the pre-molecular era of personalized cancer treatment.

PancreasFest 2009, University of Pittsburgh. Pittsburgh, PA, 07/23/2009Adjuvant and neoadjuvant approaches for localized pancreatic cancer. Fifth Annual Oncology World

Congress 2009, San Francisco, CA, 09/26/2009Carcinoid tumors of the small bowel and appendix. 2009 Neuroendocrine Tumor Symposium of the North

American Neuroendocrine Tumor Society (NANETS), Charlotte, NC, 10/02/2009Neoadjuvant therapy for pancreatic cancer. 40th Annual Meeting of the American Pancreatic Association,

Honolulu, HI, 11/07/2009Progress in the diagnosis and treatment of localized pancreatic cancer. A. Hamblin Letton Lecture; 2010

Annual scientific meeting of the Southeastern Surgical Congress. Savannah, GA, 02/21/2010The Challenge of Pancreatic Cancer. Bricker Memorial Lecture, Washington University. St. Louis, MO,

02/23/2010The critical oncologic steps in pancreaticoduodenectomy: SMA margin and vascular resection. 63rd Annual

Cancer Symposium of the Society of Surgical Oncology. St. Louis, MO, 03/05/2010Neoadjuvant and adjuvant therapy for pancreatic cancer. Second Annual Hepatic-Pancreatic-Biliary Course,

Cleveland Clinic. Cleveland, OH, 10/01/2010Distinguishing autoimmune pancreatitis from pancreatic cancer., 41st Annual Meeting of the American

Pancreatic Association, Chicago, IL, 11/06/2010Pancreatic Cancer: Treatment sequencing in localized disease., Geisinger Clinic, Danville, PA, 12/08/2010Papillary thyroid cancer: current controversies., JC Thoroughman Lectureship, Emory University, Atlanta,

GA, 02/10/2011Current Controversies in Endocrine Surgery: lymph node dissection for papillary thyroid cancer. Surgery for

pancreatic cancer: extended resection (Meet the Professor Program)., 64th Annual Cancer Symposiumof the Society of Surgical Oncology, San Antonio, TX, 03/02/2011 - 03/04/2011

Arterial and venous resection in borderline resectable adenocarcinoma of the pancreas., 11th Annual Meetingof the Americas Hepato- Pancreato- Biliary- Association (AHPBA), Miami Beach, FL, 03/10/2011

Presidential Address: Papillary Carcinoma of the Thyroid: Balancing Principles of Oncology with EmergingTechnology, 32nd Annual Meeting of the American Association of Endocrine Surgeons, Houston, TX,04/11/2011

The Pancreatic Primary: When to Enucleate and When to Resect., Society for Surgery of the AlimentaryTract/American Hepato-Biliary Association Joint Symposium, 52nd Annual Meeting of the SSAT,Chicago, IL, 05/09/2011

Multimodality Management of Localized Pancreatic Cancer, University of Colorado, Aurora, CO, 09/19/2011Personalized Medicine for Localized Pancreatic Cancer, Denver Surgical Society, Denver, CO, 09/19/2011Management of Intraoperative Bleeding at the Time of Pancreaticoduodenectomy, 97th Annual Clinical

Congress, American College of Surgeons, San Francisco, CA, 10/23/2011Surgery for Medullary Carcinoma of the Thyroid, 81st Annual Meeting of the American Thyroid Association,

Palm Springs, CA, 10/28/2011The Challenge of Pancreatic Cancer, UMNDJ Robert Wood Johnson Medical School, New Brunswick, New

Jersey, 11/09/2011Central Neck Dissection, Surgery of the Thyroid and Parathyroid Glands, Harvard Medical School, Boston,

MA, 11/11/2011Clinical State of the Art Lecture: Challenges in the Management of Neuroendocrine Tumors of the Pancreas,

The 43rd Annual Meeting of the American Pancreatic Association (combined meeting of the APA-IAP), Miami Beach, FL, 11/01/2012

Allied Health Care Symposium: Integration of Mid-Level Providers into a Busy Surgical Practice - ASurgeon's Perspective, American Hepato-Pancreato-Biliary Association Annual Meeting, MiamiBeach, FL, 02/20/2013

Controversies in Pancreatic Cancer Symposium: What is the Role of Neoadjuvant Therapeutic Treatment forResectable Cancer, 2013 Society of Surgical Oncology Annual Cancer Symposium, National Harbor,

8 / 41

MD, 03/07/2013Papillary carcinoma of the thyroid: are we complicating a simple disease?, University of Pittsburgh Medical

Center, Pittsburgh, PA, 01/22/2014Medullary Thyroid Cancer (Meet the Expert Luncheon), 100th Annual Clinical Congress, American College

of Surgeons, San Francisco, CA, 10/27/2014Surgery for Medullary Thyroid Cancer / MEN2-associated Pheochromocytoma and Hyperparathyroidism.

ATA Clinical Management Guidelines, Medulllary Thyroid Cancer., American Thyroid Association,San Diego, CA, 03/04/2015

The management of borderline resectable pancreatic cancer (Meet the Professor Session), Annual CancerSymposium of the Society of Surgical Oncology, Houston, TX, 03/27/2015

Symposium: Case Presentations with Professors and Fellows, Annual Cancer Symposium of the Society ofSurgical Oncology, Houston, TX, 03/28/2015

Medullary Thyroid Cancer (Meet the Expert Luncheon), 101st Annual Clinical Congress, American Collegeof Surgeons, Chicago, IL, 10/05/2015

Treatment sequencing for localized pancreatic cancer, Hoffman Pancreatic Cancer Symposium, Fox ChaseCancer Center, Philadelphia, PA, 10/09/2015

Interdisciplinary Management of Neuroendocrine Tumors, 3rd NY Masters Course in Endocrinology andEndocrine Surgery, New York, NY, 12/11/2015

Current Challenges in the Surgical Management of Pancreatic Cancer (Meet the Professor Breakfast); TheGreat Debates I, Resectable Pancreatic Head Adenocarcinoma, Resect First, Con; NeuroendocrineTumors Current Controversies, Resect or Observe the 1-2 cm PNET? Observe., Annual CancerSymposium of the Society of Surgical Oncology, Boston, MA, 03/04/2016 - 03/05/2016

Pancreatic cancer: when to consider surgery for a systemic disease., National Pancreas Foundation FellowsSymposium, Itasca, IL, 04/09/2016

Medical crossfire: neoadjuvant therapy for pancreas cancer., 1st Annual School of Gastrointestinal Oncology,New York, NY, 04/23/2016

Personalized Medicine for Localized Pancreatic Cancer, 1st Thomas E. Seay Lectureship, Georgia Center forOncology, Research & Education, Atlanta, GA, 09/10/2016

Medullary Thyroid Cancer (Meet the Expert), 102nd Annual Clinical Congress, American College ofSurgeons, Washington, DC, 10/17/2016

Borderline resectable pancreatic cancer., Mayo Clinic Pancreatic Cancer Conference, Scottsdale, AZ,11/19/2016

Surgical Approaches in Pancreatic Neuroendocrine Tumors, DDW Combined Clinical Symposium (SSAT)on Recent Advances in Neuroendocrine Tumors of the Pancreas; 58th Annual Meeting of the SSAT(DDW), Chicago, IL, 05/07/2017

Pancreatectomy: does the approach matter?, 58th Annual Meeting of the SSAT (DDW), Chicago, IL,05/08/2017

Medullary Thyroid Cancer (Meet the Expert), 103rd Annual Clinical Congress, American College ofSurgeons, San Diego, CA, 10/23/2017

Why Operable Pancreatic Cancer is the Best Model for Translational Research, AACR Pancreatic CancerConference - Advances in Science and Clinical Care, Boston, MA, 09/24/2018

Medullary Thyroid Cancer (Meet the Expert), 104th Annual Clinical Congress, American College ofSurgeons, Boston, MA, 10/23/2018

Management of Locally Advanced Pancreatic Ductal Adenocarcinoma: The Role of Vascular Resection andReconstruction, Annual Cancer Symposium of the Society of Surgical Oncology, San Diego, CA,03/28/2019

Neoadjuvant Therapy for Localized Pancreatic Cancer, Pancreas Cancer Conference, Piedmont Healthcare,Atlanta, GA, 10/05/2019

InternationalVascular resection based on accurate preoperative imaging for adenocarcinoma of the pancreatic head.,

TWMC International Symposium on Pancreaticoduodenectomy., Tokyo, Japan, 11/18/1995Preoperative chemoradiation and IORT in pancreatic cancer., Third International Conference on

Gastrointestinal Oncology, Bordeau, France, 09/28/1996The multimodality management of pancreatic cancer., Swedish Society for Upper Abdominal Surgery, Lund,

Sweden, 10/24/1996Controversies in the management of MEN 1 (May 10, 1999); Elective neck dissection in the treatment of

9 / 41

medullary thyroid carcinoma (May 10, 1999)., 1999 Annual Scientific Congress of the AustralasianCollege of Surgeons, Auckland, New Zealand, 05/09/1999 - 05/14/1999

Pancreatic surgery following radiation and chemotherapy., EORTC symposium on cancer of the exocrinepancreas, Hospital Paul Brousse, Villejuif, France, 09/30/1999

Islet cell carcinoma., International Association of Endocrine Surgeons, Brussels, Belgium, 08/30/2001The importance of genotype in the management of medullary thyroid cancer., The Tom Reeve Lecture, 6th

Annual Scientific Congress of the Royal Australasian College of Surgeons, Christchurch, NewZealand, 05/10/2007

Multiple lectures given over a 2-day portion of the conference, 3rd Multidisciplinary Update on Thyroid andParathyroid Surgery, Brisbane, Australia, 11/11/2009 - 11/12/2009

Point-Counterpoint: Neoadjuvant vs. Adjuvant Therapy for Resectable Pancreatic Adenocarcinoma,International Society of Gastroenterology, 2011 Gastrointestinal Oncology Conference, Arlington, VA,09/15/2011

Arterial Resection for Pancreatic Adenocarcinoma, Annual Meeting of the Americas Hepato-Pancreato-Biliary Association (AHPBA), Miami, FL, 03/31/2017

Professor Rounds: Technical Pearls during the Whipple Procedure, Annual Meeting of the Americas Hepato-Pancreato-Biliary Association (AHPBA), Miami, FL, 03/10/2018

Progress in the Management of Pancreatic Cancer, Sabga Foundation Symposium, Port of Spain, Trinidad,11/01/2018

"Aim Small Miss Small" thoughts on career development., AHPBA Fellows Conference, Charlotte, NC,08/25/2019

Vascular Involvement in Pancreatic Surgery, Professor Rounds, Annual Meeting of the Americas Hepato-Pancreato-Biliary Association (AHPBA), Miami, FL, 03/07/2020

EDITED BOOKS/JOURNALS: 1999 Evans DB, Sherman SI (guest editors). Thyroid Cancer. Sem Surg Oncol 1999; 16.2001 Evans DB (guest editor) for vanHeerden JA, Farley DR, eds. Operative Techniques in General Surgery:

Pancreatic Surgery I. Philadelphia: W. B. Saunders, Co. 2001, Vol. 3, No. 1.2002 Evans DB (guest editor) for vanHeerden JA, Farley DR, eds. Operative Techniques in General Surgery:

Pancreatic Surgery II. Philadelphia: W. B. Saunders, Co. 2002, Vol. 4, No. 2.2002 Evans DB, Pisters PWT, Abbruzzese JL. Pancreatic Cancer. New York: Springer-Verlag 2002.2004 Abbruzzese JL, Evans DB, Willett CG, Fenoglio-Preiser C. Gastrointestinal Oncology. New York:

Oxford University Press, 2004.2005 Von Hoff DD, Evans DB, Hruban RH. Pancreatic Cancer. Sudbury, MA: Jones and Bartlett, 2005.2008 Grubbs EG, Rich TA, Li G, Sturgis EM, Younes MN, Myers JN, Edeiken-Monroe B, Fornage BD,

Monroe DP, Staerkel GA, Williams MD, Waguespack SG, Hu MI, Cote G, Gagel RF, Cohen J, WeberRS, Anaya DA, Holsinger FC, Perrier ND, Clayman GL, Evans DB. Recent advances in thyroidcancer. Curr Probl Surg. 2008; 45(3):156-250.

2016 Wang TS, Evans DB. Medullary Thyroid Cancer. Switzerland: Springer International Publishing, 2016.

EDUCATIONAL PUBLICATIONS AND VIDEOS: 1985 Riccio JC, Evans DB, MacKay DN. Mycoplasma hominis sternal wound infection. Infections in Surgery

1985; 4(12):856-859.1985 Evans DB. Primary respiratory alkalosis as the initial manifestation of sepsis. Contemporary Surgery

1985; 27:65-67.1986 Riccio JC, Evans DB, MacKay DN. Mycoplasma hominis sternal wound infection. Infections in

Medicine 1986; 3(2):83-87.1986 Li CM, Evans DB, Pettit RJ. Torsion of the gallbladder. Surgical Rounds 1986; 9(4):105-108.1991 Evans DB, et al. Questions and answers: pancreatic cancer patient booklet, 1991; second printing 1993,

third printing 2001.1992 Rich TA, Ames FC, Evans DB, Ota DM, Charnsangavej C. Intraoperative radiation therapy. M. D.

Anderson Oncology 1992; 7(3):1-11.03/19/1993 Demers ML, Evans DB, Hickey RC. Insulinoma of the pancreatic head: localization and surgical

resection. (Cine' Med Surgical Clinic). Program of the 46th Annual Cancer Symposium of the Societyof Surgical Oncology, Los Angeles, CA, March 19, 1993 (video). Presented at the Endocrine SurgeryFilm Symposium, American College of Surgeons Meeting, San Francisco, October 11, 1993.

10 / 41

1993 Ota DM, Evans DB, Skibber JM. Laparoscopic surgery in cancer management. M. D. AndersonOncology 1993; 8(3):1-9.

1993 Reilly JA, Evans DB, Merrell RC. The surgical management of patients with medullary thyroidcarcinoma (MTC) and MEN 2A. (Cine' Med Surgical Clinic) Program of the 61st Annual ScientificAssembly of the Southeastern Surgical Conference, 1993; 34 (video). Presented at the Motion PictureExhibition, American College of Surgeons Meeting, Chicago, October 10, 1994.

1994 Evans DB. Is surgery improving cure rates for pancreatic adenocarcinoma? Collected Letters in Surgery1994; 17:4-7.

1995 Davidson BS, Lee JE, Pisters PWT, Ames FC, Evans DB. Teaching complex surgery: a standardizedapproach to pancreaticoduodenectomy. Surgical Rounds 1995; 18:450-457.

1995 Evans DB. Are Thyroglobulin levels different in thyroid vs nonthyroid cancers? "Oncology Rounds"Oncology News International 1995; 4:42-43.

1995 Evans DB, Sherman SI. Iodine-131 scanning following thyroidectomy. Collected Letters in Surgery1995; 18:5-7.

1995 Cusack JC, Evans DB. Unsuspected tumor invasion of the superior mesenteric - portal vein confluenceduring pancreaticoduodenectomy. Chirurgia International; April 5, 1995 issue: pp 16-18.

04/1997 Lee JE, Pisters PWT, Evans DB. Surgical treatment of resectable adenocarcinoma of the pancreatichead. (Cine' Surgical Clinic). Program of the 10th National Congress of the Italian Society ofMultispecialty General Surgery, April, 1997 (video).

1997 Gagel RF, Sellin RV, Raney RB, Evans DB, Fornage BD, Goepfert H. Familial papillary thyroidcarcinoma. Oncology (Case Reports and Review) 1997; 12:1-6.

1998 Breslin T, Evans DB. Management of Pancreatic Cancer. Commission on Cancer, American College ofSurgeons, 1998 (video).

03/05/1999 Lee JE, Pisters PWT, Evans DB. Venous resection and reconstrucction at the time ofpancreaticoduodenectomy. (Cine' Surgical Clinic). Program of the 52nd Annual Cancer Symposium ofthe Society of Surgical Oncology, Orlando, FLA, March 5, 1999 (video).

03/15/2002 Albo D, Evans DB. Total pancreatectomy for massive cystic replacement of the pancreas in apatient with von Hippel-Lindau disease. (Cine' Surgical Clinic) 55th Annual Cancer Symposium of theSociety of Surgical Oncology, Denver, CO, March 15, 2002 (video).

10/07/2002 Albo D, Evans DB. Total pancreatectomy for massive cystic replacement of the pancreas in apatient with von Hippel-Lindau disease. 88th Annual Clinical Congress, American College ofSurgeons, San Francisco, October 7, 2002 (video).

10/20/2003 Lee JE, Pisters PWT, Evans DB. Pancreaticoduodenectomy. 89th Annual Clinical Congress,American College of Surgeons, Chicago, IL, October 20, 2003 (video).

2006 Habra MA, Jimenez C, Wallace M, Evans DB, Vassilopoulou-Sellin R. Insulinoma in a marathonrunner illustrating the effects of exercise on insulin sensitivity and glucose homeostasis. TheEndocrinologist. 2006; 16(1):1-5.

2016 Younan G, Chimukangara M, Tsai S, Evans DB, Christians K. Replaced gastroduodenal artery: Addedbenefit of the "artery first" approach during pancreaticoduodenectomy - A case report. Int J Surg CaseRep. 2016;23:93-7. PMID 27124718

INVITED ARTICLES IN JOURNALS: 1987 Evans DB, Crichlow RW. Carcinoma of the male breast and Klinefelter's Syndrome. CA - A Cancer J

for Clinicians 1987; July/Aug:246-51.1991 Evans DB, Skibber JM, Ames FC, Rich TA. Extended surgical resection for adenocarcinoma of the

pancreas. Cancer Bulletin 1991; 43(3):279-282.1992 Byrd DR, Mansfield PF, Evans DB. Pancreatic Cancer: biology and changing clinical management.

Cancer Bulletin 1992; 44:292-300.1994 Evans DB, Lee JE, Merrell RC, Hickey RC. Andrenal medullary disease in MEN 2: appropriate

management. Endocrinology and Metabolism Clinics of North America. 1994; 23:167-176.1994 Leach SD, Rich TA, Abbruzzese JL, Lee JE, Cleary KR, Charnsangavej C, Ames FC, Buchholz DJ,

Fenoglio CJ, Stanford P, Evans DB. Preoperative chemoradiation, pancreaticoduodenectomy, andexternal-beam intraoperative radiation therapy for pancreatic adenocarcinoma: the M. D. Andersonexperience. Cancer Bulletin 1994; 46:518-524.

1994 Rich TA, Evans DB, Curley SA, Ajani JA. Adjuvant radiotherapy and chemotherapy for biliary andpancreatic cancer. Ann Oncol 1994; 5 (Suppl 3): S75-S80.

1995 Evans DB, Lee JE, Leach SD, Fuhrman GM, Cusack JC, Rich TA. Vascular resection and intraoperatie

11 / 41

radiation therapy during pancreaticoduodenectomy: rationale and technique. Adv in Surgery 1995;29:235-262.

1995 Cote GJ, Wohllk N, Evans DB, Goepfert H, Gagel RF. RET proto-oncogene mutations in multipleendocrine neoplasia type 2 and medullary thyroid carcinoma. Bailliere's Clinical Endocrinology andMetabolism 1995; 9:609-630.

1995 Evans DB, McMasters KM, Lee JE. Medullary thyroid carcinoma. Current Surgery 1995; 52:130-136.1995 Lee JE, Evans DB. Adenocarcinoma of the pancreas. Current Surgery 1995; 52:106-111.1995 Evans DB, Abbruzzese JL, Lee JE, Leach SD, Charnsangavej C, Cleary KR, Buchholz DJ, Rich TA.

Preoperative chemoradiation for adenocarcinoma of the pancreas: M. D. Anderson experience.Seminars Surg Oncol 1995; 11:132-140.

1995 Rich TA, Curley SA, Evans DB, Leach SD, Lowy AM, Skibber JM. Intraoperative radiotherapyexperience at M. D. Anderson Cancer Center. In Kogelnik HD, ed. Progress in Radio-Oncology V.Bologna, Italy: Monduzzi Editore, 1995, 579-583.

1995 Rich TA, Evans DB. Preoperative combined modality therapy for pancreatic cancer. World J Surg.1995; 19:264-269.

1996 Evans DB, Staley CA, Lee JE, Pisters PWT, Abbruzzese JL. Adenocarcinoma of the pancreas: recentcontroversies, current management, and future therapies. GI Cancer 1996; 1:149-161.

1996 Wohllk N, Cote G, Evans DB, Goepfert H, Ordonez N, Gagel RF. Application of genetic screeninginformation to the management of medullary thyroid carcinoma and multiple endocrine neoplasia type2. Endocrinology and Metabolism Clinics of North America 1996; 25:1-25.

1997 Evans DB, Lee JE, Pisters PWT, Charnsangavej C, Ellis LM, Chiao PJ, Lenzi R, Abbruzzese JL.Advances in the diagnosis and treatment of adenocarcinoma of the pancreas. In Pollock RE, Ed.Cancer Treatment and Research. 1997; 90:109-125.

1997 Evans DB, Jessup JM, Colacchio T. Society of Surgical Oncology practice guidelines: Pancreatic cancerpracctice guidelines. Oncology 1997; 11:1074-1079.

1997 Lee JE, Evans DB. Advances in the diagnosis and treatment of gastrointestinal neuroendocrine tumors.In Pollock RE, ed. Cancer Treatment and Research. 1997; 90:227-238.

1997 Evans DB, Jessup JM, Colacchio T. Society of Surgical Oncology practice guidelines: Gastric cancerpractice guidelines. Oncology 1997; 11:1067-1072.

1997 Evans DB, Pisters PWT, Lee JE. Multimodality therapy for adenocarcinoma of the pancreas: The M. D.Anderson experience. Problems in General Surgery 1997; 14:117-124.

1998 Evans DB, Pisters PWT, Lee JE, Bold RJ, Charnsangavej C, Janjan NA, Wolff RA, Abbruzzese JL.Preoperative chemoradiation strategies for localized adenocarcinoma of the pancreas. J Hepato-biliary-panc Surg 1998; 5:242-250.

1998 Lee JE, Pisters PWT, Evans DB. Treatment of resectable adenocarcinoma of the pancreatic head.Gastroenterology International 1998; 10:517-518.

1998 Miller AR, Pisters PWT, Lee JE, Janjan NA, Abbruzzese JL, Evans DB. Preoperative chemoradiationand pancreaticoduodenectomy for adenocarcinoma of the pancreas. Hepato-Gastroenterology 1998;45:624-633.

1998 Breslin TM, Janjan NA, Lee JE, Pisters PWT, Wolff RA, Abbruzzese JL, Evans DB. Neoadjuvantchemoradiation for adenocarcinoma of the pancreas. Frontiers in Bioscience 1998; 3: E193-203.

1998 Pearson AS, Bouvet M, Evans DB, Roth JA. Gene therapy and pancreatic cancer. Frontiers inBioscience 1998; 3: E230-237.

1998 Miller AR, Robinson EK, Lee JE, Pisters PWT, Chiao PJ, Lenzi R, Abbruzzese JL, Evans DB.Neoadjuvant chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. SurgOncol Clinics of North Amer 1998; 7:183-197.

1998 Yeo CJ, Hruban RH, Conlon KC, Sarr MG, Lillemoe KD, Evans DB, Jaffee EM. Pancreatic cancer:1998 update. J Am Coll Surg 1998; 187:429-442.

1999 Evans DB, Fleming JB, Lee JE, Cote G, Gagel RF. The surgical treatment of medullary thyroidcarcinoma. Sem Surg Oncol 1999; 16:50-63.

2000 Evans DB. What's new in Surgery 2000: surgical oncology. J Am Coll Surg 2000; 190:215-226.2000 Windham TC, Pearson AS, Skibber JM, Mansfield PF, Lee JE, Pisters PWT, Evans DB. Significance

and management of local recurrences and limited metastatic disease in the abdomen. Surg Clinics ofNorth Amer 2000; 80:761-774.

2000 Wolff RA, Chiao P, Lenzi R, Pisters PWT, Lee JE, Janjan NA, Crane CH, Evans DB, Abbruzzese JL.Current approaches and future strategies for pancreatic carcinoma. Invest New Drugs 2000; 18:43-56.

2000 Hawes RH, Xiong Q, Waxman I, Chang KJ, Evans DB, Abbruzzese JL. A multispecialty approach to

12 / 41

the diagnosis and management of pancreatic cancer. Amer J Gastroenterology 2000; 95:17-31.2000 Tyler DS, Shaha AR, Udelsman RA, Sherman SI, Thompson NW, Evans DB. Thyroid Cancer: 1999

update. Ann Surg Oncol 2000; 7:376-398.2001 Lillemoe KD, Conlon KC, Evans DB, Warshaw AL. Ductal adenocarcinoma of the pancreas: part 1:

diagnosis and staging. Contemporary Surg 2001; 57:68-76.2001 Evans DB. Preoperative chemoradiation for resectable and locally advanced adenocarcinoma of the

pancreas. J Gastrointestinal Surg 2001; 5:2-5.2001 Evans DB, Wolff RA, Crane CH. Neoadjuvant strategies for pancreatic cancer. Oncology 2001;

15:727-737.2001 Wayne JD, Wolff RA, Pisters PWT, Evans DB. Multimodality management of localized pancreatic

cancer. The Cancer J 2001; 7(suppl 1):s35-s46.2001 Crane CH, Wolff RA, Abbruzzese JL, Evans DB, Milas L, Mason K, Charnsangavej C, Pisters PWT,

Lee JE, Lenzi R, Lahoti S, Vauthey JN, Janjan NA. Combining gemcitabine with radiation inpancreatic cancer: understanding important variables influencing the therapeutic index. Semin Oncol.2001; 28(3 Suppl 10):25-33.

2001 Dackiw APB, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg 2001;25:914-926.

2001 Lillemoe KD, Conlon KC, Evans DB, Warshaw AL. Ductal adenocarcinoma of the pancreas: part 2:surgical and adjuvant therapies. Contemporary Surg 2001; 57:110-120.

2002 Wayne JD, Abdalla EK, Wolff RA, Crane CH, Pisters PWT, Evans DB. Localized adenocarcinoma ofthe pancreas: The rationale for preoperative chemoradiation. The Oncologist 2002; 7:34-45.

2003 Crane CH, Beddar AS, Evans DB. The role of intraoperative radiotherapy in pancreatic cancer. SurgOncol Clin N Am 2003; 12:965-977.

2003 Sclabas GM, Fujioka S, Schmidt C, Evans DB, Chiao PJ. NF-kappaB in pancreatic cancer. Int JGastrointest Cancer. 2003; 33:15-26.

2004 Doherty GM, Yip L, Lee JE, Shapiro SE, Waguespack SG, Sherman SI, Hoff AO, Gagel RF, Arens JF,Evans DB. Surgical management of hereditary pheochromocytoma: Invited commentary Journal of theAmerican College of Surgeons. April 2004;198(4):534-535.

2004 Andtbacka RH, Evans DB, Pisters PW. Surgical and endoscopic palliation for pancreatic cancer.Minerva Chir. 2004; 59(2):123-36.

2004 Raut CP, Evans DB, Crane CH, Pisters PWT, Wolff RA. Neoadjuvant therapy for resectable pancreaticcancer. Surg Oncol Clin N Am. 2004; 4:639-61.

2005 Evans DB. Preoperative chemoradiation for pancreatic cancer. Semin Oncol. 2005; 32:25-9.2005 Kouvaraki MA, Shapiro SE, Lee JE, Evans DB, Perrier ND. Surgical management of thyroid

carcinoma. J Natl Compr Canc Netw. 2005; 3(3):458-66.2005 Varadhachary GR, Tamm EP, Crane C, Evans DB, Wolff RA. Borderline resectable pancreatic cancer.

Curr Treat Options Gastroenterol. 2005; 8(5):377-84.2005 Wong AA, Delclos ME, Wolff RA, Evans DB, Abbruzzese JL, Tamm EP, Xiong HO, Ho L, Crane CH.

Pancreatic Tumor Study Group. Radiation dose considerations in the palliative treatment of locallyadvanced adenocarcinoma of the pancreas. Am J Clin Oncol. 2005; 28(3):227-33.

2005 Kouvaraki MA, Solorzano CC, Shapiro SE, Yao JC, Perrier ND, Lee JE, Evans DB. Surgical treatmentof non-functioning pancreatic islet cell tumors. J Surg Oncol. 2005; 89(3):170-85.

2005 Pisters PWT, Wolff RA, Crane CH, Evans DB. Combined-modality treatment for operable pancreaticadenocarcinoma. Oncology 2005; 19(3):393-404, 409; discussion 409-10, 412-6.

2006 Rodgers SE, Evans DB, Lee JE, Perrier ND. Adrenocortical carcinoma. Surg Oncol Clin N Am. 2006;15(3): 535-53.

2006 Evans DB. Resectable pancreatic cancer: the role for neoadjuvant/preoperative therapy. HPB 2006;8(5):365-368.

2006 Jiao L, Bondy ML, Hassan MM, Wolff RA, Evans DB, Abbruzzese JL, Li D. Selected polymorphismsof DNA repair genes and risk of pancreatic cancer. Cancer Detect Prev. 2006; 30(3):284-91.

2006 Al-Refaie WB, Choi EA, Tseng JF, Tamm EP, Lee JH, Lee JE, Evans DB, Pisters PW. Intraductalpapillary mucinous neoplasms of the pancreas. Med Princ Pract. 2006; 15(4):245-52.

2006 Crane CH, Varadhachary G, Wolff RA, Pisters PW, Evans DB. The argument for pre-operativechemoradiation for localized, radiographically resectable pancreatic cancer. Best Pract Res ClinGastroenterol. 2006; 2:365-82.

2006 Tseng JF, Tamm EP, Lee JE, Pisters PW, Evans DB. Venous resection in pancreatic cancer surgery.Best Pract Res Clin Gastroenterol. 2006; 2:349-64.

13 / 41

2007 Grubbs EG, Evans DB. Role of lymph node dissection in primary surgery for thyroid cancer. J NatlCompr Canc Netw. 2007; 5(6):623-30.

2007 Crane CH, Varadhachary G, Pisters PW, Evans DB, Wolff RA. Future chemoradiation strategies inpancreatic cancer. Semin Oncol. 2007; 34(4):335-46.

2007 Mittendorf EA, Evans DB, Lee JE, Perrier ND. Pheochromocytoma: advances in genetics, diagnosis,localization, and treatment. Hematol Oncol Clin North Am. 2007(3):509-25.

2009 Kim MP, Evans DB, Vu TM, Fleming JB. The recognition and surgical management of heritable lesionsof the pancreas. Surg Oncol Clin N Am. 2009; 18(1):99-119.

2009 Callender GG, Kennamer DL, Grubbs EG, Lee JE, Evans DB, Perrier ND. Posteriorretroperitoneoscopic adrenalectomy. Adv Surg. 2009; 43:147-57.

2009 Crane CH, Varadhachary G, Settle SH, Fleming JB, Evans DB, Wolff RA. The integration ofchemoradiation in the care of patients with localized pancreatic cancer. Cancer Radiother. 2009;13(2):123-43.

2009 Ying AK, Huh W, Bottomley S, Evans DB, Waguespack SG. Thyroid cancer in young adults. SeminOncol. 2009; 36(3):258-74.

2010 Christians KK, Lal A, Pappas S, Quebbeman E, Evans DB. Portal vein resection. Surg Clin North Am.2010; 90(2):309-22.

2010 Lal A, Christians K, Evans DB. Management of borderline resectable pancreatic cancer. Surg OncolClin N Am. 2010; 19(2):359-70.

2012 Appel BL, Tolat P, Evans DB, Tsai S. Current Staging systems for pancreatic cancer. Cancer J.2012;18(6):539-49.

2013 Christians KK, Tsai S, Tolat PP, Evans, DB. Critical steps for pancreaticoduodenectomy in the settingof pancreatic adenocarcinoma. J Surg Oncol. 2013;107(1):33-8.

2014 Lai V, Evans DB, Wang TS. Central compartment lymph node dissection for differentiated thyroidcancer: review of the literature. Int. J. Endo. Oncol. 2014;1(1):41-48.

2016 Tsai S, Erickson BA, Dua K, Ritch PS, Tolat P, Evans DB. Evolution of the Management of ResectablePancreatic Cancer. J Oncol Pract. 2016;12(9):772-8. PMID 27621326

2016 Asare EA, Evans DB, Erickson BA, Aburajab M, Tolat P, Tsai S. Neoadjuvant treatment sequencingadds value to the care of patients with operable pancreatic cancer. J Surg Oncol. 2016;114(3):291-5.PMID 27264017

2016 Tsai S, Christians KK, Ritch PS, George B, Khan AH, Erickson B, Evans DB. Multimodality Therapyin Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Importance ofLocoregional Therapies for a Systemic Disease. J Oncol Pract. 2016;12(10):915-923. PMID 27858562

2016 Younan G, Tsai S, Evans DB, Christians KK. Techniques of Vascular Resection and Reconstruction inPancreatic Cancer. Surg Clin North Am. 2016;96(6):1351-1370. PMID 27865282

2016 Tsai S, Evans DB. Therapeutic Advances in Localized Pancreatic Cancer. JAMA Surg.2016;151(9):862-8. PMID 27276001

2018 Evans DB. What Makes a Pancreatic Cancer Resectable? Am Soc Clin Oncol Educ Book.2018;(38):300-305. PMID 30231408

VISITING PROFESSORSHIPS: 04/21/1997 - 04/23/1997 Duke University04/11/2000 - 04/12/2000 Northwestern University04/10/2001 - 04/11/2001 University of Chicago04/18/2002 - 04/19/2002 University of South Florida06/03/2002 - 06/13/2002 Gastroenterological Society of Queensland, Australia04/16/2003 - 04/17/2003 University of Tennessee06/03/2003 - 06/05/2003 University of Cincinnati (Barrows Visiting Professor)03/11/2004 - 03/13/2004 University of Iowa (Research Day Visiting Professor)08/12/2004 Massachusetts General Hospital03/10/2005 - 03/11/2005 Boston University (Mozden Professorship)02/21/2006 - 02/22/2006 University of Wisconsin02/28/2006 - 03/01/2006 University of Massachusetts03/11/2006 - 03/14/2006 Australasian Pancreatic Club/Sydney GI Surgical Society, Sydney, Australia04/11/2006 - 04/12/2006 University of Utah02/25/2007 - 02/27/2007 Memorial Sloan-Kettering Cancer Center (19th Annual Surgical Fellows

Distinguished Visiting Professor)

14 / 41

04/10/2007 - 04/11/2007 Beth Israel-Deaconess Medical Center (Visiting Lecturer in HPB Surgery, HarvadMedical School)

05/07/2007 - 05/11/2007 RACS Visitor in Surgical Oncology, The Royal Australasian College of SurgeonsAnnual Scientific Congress, Christchurch, NZ

01/17/2008 - 01/18/2008 Mayo Clinic (Oliver H. Beahrs Visiting Professorship)01/30/2008 - 01/31/2008 Johns Hopkins University (William Lees Thyroid Tumor Center Professorship)05/21/2008 University of California San Diego (Nicholas A. Halasz Visiting Professor)09/18/2008 Johns Hopkins University (Frieda Deutsch Lectureship in Pancreatic Cancer)06/18/2009 University of Alabama (Resident Research Day Visiting Professor)02/01/2010 Albert Einstein College of Medicine (Masters of Surgery Visiting Professor)10/14/2010 - 10/15/2010 Wayne State University, David Fromm Research Day (Scott Warner Woods

Endowed Lecturer)11/03/2011 - 11/04/2011 The Ohio State University (Michael J. Walker Lecture in Surgical Oncology)10/25/2012 - 10/26/2012 Vanderbilt University (Leonard W. Edwards Lecturer)11/15/2012 - 11/17/2012 Carolinas Medical Center (Marie Claire Marroum Rare and Complex Cancers

Lecturer)01/09/2013 - 01/11/2013 University of Calgary (Roy Preshaw Academic Lecture / Resident and Fellow

Research Day)04/30/2013 - 05/04/2013 University of Melbourne, Australia (2013 Royal Melbourne Hospital International

Visitor)05/06/2013 - 05/07/2013 Royal Australasian College of Surgeons Annual Scientific Congress, Auckland,

New Zealand06/10/2014 - 06/11/2014 University of Iowa (Carol Scott-Conner Visiting Professor)06/16/2015 - 06/17/2015 Yale University (Cahow Lecture)09/28/2015 - 09/29/2015 University of California, Davis Medical Center (Inaugural Charlie Frey Lecture)11/17/2015 - 11/18/2015 Indiana University (William C. Moore Visiting Professor)04/19/2016 - 04/20/2016 West Virginia University (Donald Morton Visiting Professor)09/07/2016 Loyola University (Gerard V. Aranha Lecture in Surgical Oncology)11/29/2016 - 11/30/2016 University of Nebraska (Daniel M. Miller Distinguished Lecture in Surgical

Oncology)10/02/2017 - 10/03/2017 University of California, Davis (Charles F. Frey Lectureship)06/06/2018 - 06/07/2018 Northwestern University (Rolfe Lecture)10/02/2019 - 10/03/2019 University of California, Irvine

BIBLIOGRAPHYRefereed Journal Publications/Original Papers1. Cohen SR, Evans DB, Kruger RS: A simple collecting system for leakage of ascitic fluid. Surg Gyn Obstet

1988;167:515-16.2. Evans DB, Skibber JM, Ames FC, Rich TA. Extended surgical resection for adenocarcinoma of the pancreas

Cancer Bulletin. 1991;43(3):279-282. 3. Evans DB, Rich TA, Byrd DR, Ames FC. Adenocarcinoma of the pancreas: current management of resectable

and locally advanced disease. Southern Medical J 1991;84:566-70.4. El-Naggar AK, Evans DB, MacKay B. Oncocytic adrenal cortical carcinoma. J Ultrastructural Pathology

1991;15:540-547.5. Evans DB, Byrd DB, Mansfield PF. Preoperative chemoradiotherapy for adenocarcinoma of the pancreas:

rationale and technique. Am J Clin Oncol 1991;14:359-364.6. Evans DB, Shumate CR, Ames FC, and Rich TA. Use of dexon mesh for abdominal partitioning above the

peritoneal reflection. Dis Colon & Rectum 1991;34:833-835.7. Lew Y, Jones DV, Mars WM, Evans DB, Byrd DR, Frazier ML. Expression of Elongation Factor-1 Gamma-

related sequence in human pancreatic cancer. Pancreas 1992;7:144-152.8. Ellis LM, Evans DB, Martin D, Ota DM. Laparoscopic feeding jejunostomy tube in oncology patients.

Surgical Oncol 1992;1:245-249.9. Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, Charnsangavej C, Fenoglio CJ, Ames FC.

Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. ArchSurg 1992;127:1335-1339.

10. Evans DB, Termuhlen PM, Byrd DR, Ames FC, Ochran TG, Rich TA. Intraoperative radiation therapy

15 / 41

following pancreaticoduodenectomy. Ann Surg 1993;218:54-60.11. Davidson BS, Lee JE, Dodd L, Dimopoulos M, Evans DB. Extramedullary plasmacytoma of the pancreas.

Am J Clin Oncol 1993;16(4):363-368.12. Thomas SM, Fitzgerald JB, Pollock RE, Evans DB. Isolated splenic metastases from colon carcinoma. Eur J

Surg Oncol 1993;19:485-490.13. Ajani JA, Mayer RJ, Ota DM, Steel GD, Evans DB, Roh M, Sugarbaker J, Dumas P, Gray C, Vena D,

Stablein D. Preoperative and postoperative combination chemotherapy for potentially resectablegastric carcinoma. J Natl Cancer Inst 1993;85:1839-1844.

14. Evans DB, Skibber JM, Lee JE, Ajani JA, Gagel RF, Sellin RV, Fenoglio CF, Merrell RC, Hickey RC.Nonfunctioning islet cell carcinoma of the pancreas. Surgery 1993;114:1175-82.

15. Fuhrman GM, Charnsangavej C, Abbruzzese JL, Martin RG, Fenoglio CF, Evans DB. Thin-section contrastenhanced computed tomography accurately predicts resectability of malignant pancreatic neoplasms.Am J Surg 1994;167: 104-113.

16. Tyler DS, Evans DB. Reoperative pancreaticoduodenectomy. Ann Surg 1994;2:211-221.17. Cusack JC, Fuhrman GM, Lee JE, Evans DB. Management of unsuspected tumor invasion of the superior

mesenteric-portal venous confluence at the time of pancreaticoduodenectomy. Am J Surg1994;168:352-354.

18. Curley SA, Evans DB, Ames FC. Resection for cure of carcinoma of the colon directly invading theduodenum or pancreatic head. J Amer. Col. Surg 1994;179:587-592.

19. Tyler DS, Winchester DJ, Caraway NP, Hickey RC, Evans DB. Indeterminate fine needle aspiration biopsyof the thyroid: identification of subgroups at high risk for invasive carcinoma. Surgery1994;116:1054-1060.

20. Robins DB, Katz RL, Evans DB, Atkinson EN, Green L. Fine-needle aspiration of the pancreas: in quest ofaccuracy. Acta Cytologica 1995;39:1-10.

21. Gagel RF, Cote GJ, Martins Bugalho MJG, Boyd AE, Cummings T, Goepfert H, Evans DB, Cangir A,Khorana S, Schultz PN. Clinical use of molecular information in the management of multipleendocrine neoplasia type 2A. J Internal Med 1995;238:333-341.

22. Jones DV, Sugarman SM, Markowitz AB, Levin B, Abbruzzese JL, Evans DB, Charnsangavej C, Smith R,Patt YZ. Cisplatin, 5-fluorouracil, and leucovorin in the therapy of adenocarcinomas of the pancreas.Oncol Reports 1995;2:1121-1123.

23. Leach SD, Rose JA, Lowy AM, Lee JE, Charnsangavej C, Abbruzzese JL, Katz RL, Evans DB. Significanceof peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreatic head.Surgery 1995;118:472-478.

24. Evans DB, Abbruzzese JL, Cleary KR, Lee JE, Buchholz DJ, Rich TA. Rapid-fractionation preoperativechemoradiation for malignant periampullary neoplasms. J. R. Coll Surg Edinb 1995;40:319-323.

25. Evans DB, Abbruzzese JL, Cleary KR, Buchholz DJ, Fenoglio CJ, Collier C, Rich TA. Preoperativechemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepaticirradiation. Int. J Radiation Oncology Biol. Phys 1995;33:913-918.

26. Lee JE, Berger DH, El-Naggar AK, Hickey RC, Sellin RV, Gagel RF, Burgess MA, Evans DB. Surgicalmanagement, DNA content, and patient survival in adrenal cortical carcinoma. Surgery1995;118:1090-1098.

27. Staley CA, Lee JE, Cleary KA, Abbruzzese JL, Fenoglio CJ, Rich TA, Evans DB. Preoperativechemoradiation pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma ofthe pancreatic head. Am J Surg 1996;171:118-125.

28. Fuhrman GM, Leach SD, Staley CA, Cusack JC, Charnsangavej C, Cleary KR, El-Naggar AK, Fenoglio CJ,Lee JE, Evans DB. Rationale for en-bloc vein resection in the treatment of pancreatic adenocarcinomaadherent to the superior mesenteric-portal vein confluence. Ann Surg 1996;223:154-162.

29. Frazier ML, Fernandez E, deLlorens R, Brown NM, Pathak S, Cleary KR, Abbruzzese JL, Berry K, Olive M,LeMaistre A, Evans DB. Pancreatic adenocarcinoma cell line, MDAPanc-28 with features of bothacinar and ductal cells. Int. J Pancreatol 1996;19:31-38.

30. Leach SD, Davidson BS, Ames FC, Evans DB. Alternative Method for exposure of the retropancreaticmesenteric vasculature during total pancreatectomy. J Surg Oncol 1996;61:163-165.

31. Evans DB, Frazier ML, Charnsangavej C, Katz RL, Larry L, Abbruzzese JL. Molecular diagnosis ofexocrine pancreatic cancer using a percutaneous technique. Ann Surg Oncol 1996;3:241-246.

32. Staley CA, Cleary KA, Abbruzzese JA, Lee JE, Ames FC, Fenoglio CJ, Evans DB. Need for standardizedpathologic staging of pancreaticoduodenectomy specimens. Pancreas 1996;12:373-380.

16 / 41

33. Loyer EM, David CL, Dubrow RA, Evans DB, Charnsangavej C. Vascular involvement in pancreaticadenocarcinoma: reassessment by thin-section CT. Abdom Imaging 1996;21:202-206.

34. Lee JE, Lowy AM, Thompson WA, Lu M, Loflin PT, Skibber JM, Evans DB, Curley SA, Mansfield PF,Reveille JD. Association of gastric adenocarcinoma with the human leukocyte antigen class II geneDQB1*0301. Gastroenterology 1996;111:426-432.

35. Robinson EK, Lee JE, Pisters PWT, Evans DB. Reoperative pancreaticoduodenectomy for periampullarycarcinoma. Am J Surg 1996;172:432-438.

36. Lee JE, Curley SA, Gagel RF, Evans DB, Hickey RC. Cortical-sparing adrenalectomy for patients withbilateral pheochromocytoma. Surgery 1996;120:1064-1071.

37. Sinicrope FA, Evans DB, Leach SD, Cleary KR, Fenoglio CJ, Lee J, Abbruzzese JL. bcl-2 and p53expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin CancerRes 1996;2:2015-2022.

38. Wohllk N, Cote GJ, Bugalho MMJ, Ordonez N, Evans DB, Goepfert H, Khorana S, Schultz P, Richards CS,Gagel RF. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. JClin Endocrinol Metab 1996;10:3740-3745.

39. Spitz FR, Abbruzzese JL, Lee JE, Pisters PWT, Lowy AM, Fenoglio CJ, Cleary KR, Janjan NA, GoswitzMS, Rich TA, Evans DB. Preoperative and postoperative chemoradiation strategies in patients treatedwith pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997;15:928-937.

40. Sloan DA, Donnelly MB, Schwartz RW, Plymale MA, Strodel WE, Kenady DE, McGrath PC, Edwards MJ,Singletary SE, Evans DB, Souba WW, Bland KI. The multidisciplinary structured clinical instructionmodule as a vehicle for cancer education. Am J Surg 1997;173:220-225.

41. Abbruzzese JL, Evans DB, Raijman I, Larry L, King T, Leach SD, Frazier ML. Detection of mutated c-Ki-ras in the bile of patients with pancreatic cancer. Anticancer Res 1997;17:795-802.

42. Sloan DA, Donnelly MB, Plymale MA, Schwartz RW, Edwards MJ, Singletary SE, Evans DB, Souba WW,Gadd M, Bland KI, the Breast Cancer Education Working Group. Improving residents' clinical skillswith the structured clinical instruction module for breast cancer: Results of a multi-institutional study.Surgery 1997;122:324-334.

43. Grau AM, Zhang L, Wang W, Ruan S, Evans DB, Abbruzzese JL, Zhang W, Chiao PJ. Induction ofp21waf1 expression and growth inhibition by transforming growth factor-? involve the tumorsuppressor gene DPC4 in human pancreatic adenocarcinoma cells. Cancer Res 1997;57:3929-3934.

44. Lowy AM, Lee JE, Pisters PWT, Davidson BS, Fenoglio CJ, Stanford P, Jinnah R, Evans DB. Prospective,randomized trial of octreotide to prevent pancreatic fistula following pancreaticoduodenectomy formalignant disease. Ann Surg 1997;226:632-641.

45. McMasters KM, Tuttle TM, Leach SD, Rich TA, Cleary KR, Evans DB, Curley SA. Neoadjuvantchemoradiation for extrahepatic cholangiocarcinoma. Am J Surg 1997;174:605-609.

46. Wang M, Abbruzzese JL, Friess H, Hittelman WN, Evans DB, Abbruzzese MC, Chiao P, Donghui L. DNAadducts in human pancreatic tissues and their potential role in carcinogenesis. Cancer Res1998;58:38-41.

47. Ellis LM, Takahashi Y, Fenoglio CJ, Cleary KR, Bucana CD, Evans DB. Vessel counts and vascularendothelial growth factor expression in pancreatic adenocarcinoma. Eur J Cancer 1998;34:337-340.

48. Bouvet M, Staerkel GA, Spitz FR, Curley SA, Charnsangavej C, Hagemeister FB, Janjan NA, Pisters PWT, Evans DB. Primary pancreatic lymphoma. Surgery 1998;123:382-390.

49. Leach SD, Lee JE, Charnsangavej C, Cleary KR, Lowy AM, Fenoglio CJ, Pisters PWT, Evans DB. Survivalfollowing pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluencefor adenocarcinoma of the pancreatic head. Brit J Surg 1998;85:611-617.

50. Robinson EK, Grau AM, Evans DB, Smid CM, Chiao PJ, Abbruzzese JL, Grimm EA. Cell cycle regulationof human pancreatic cancer by tamoxifen. Ann Surg Oncol 1998;5:342-349.

51. Cote GJ, Lee JE, Evans DB, Huang E, Schultz PN, Dang GT,Qui H, Shefelbine S, Sellin RV, Gagel RF.Five novel mutations in the familial endocrine neoplasia type 1 (MEN1) gene. (Mutation in Brief no.188 online) Human Mutation 1998;12:219.

52. Lee JE, Evans DB, Hickey RC, Sherman SI, Gagel RF, Abbruzzese MC, Abbruzzese JL. Unknown primarycancer presenting as an adrenal mass: frequency and implications for diagnostic evaluation of adrenalincidentalomas. Surgery 1998;124:1115-1122.

53. Bouvet M, Bold RJ, Lee J, Evans DB, Abbruzzese JL, Chiao PJ, McConkey DJ, Chandra J, Chada S, FangB, Roth JA. Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis andsuppresses growth of human pancreatic cancer. Ann Surg Oncol 1998;5:681-688.

17 / 41

54. Pisters PWT, Abbruzzese JL, Janjan NA, Cleary KR, Charnsangavej C, Goswitz MS, Rich TA, Raijman I,Wolff RA, Lenzi R, Lee JE, Evans DB. Rapid-fractionation preoperative chemoradiation,pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreaticadenocarcinoma. J Clin Oncol 1998;16:3843-3850.

55. Hunt KK, Fleming JB, Abramian A, Zhang L, Evans DB, Chiao PJ. Overexpression of the tumor suppressorgene Smad4/DPC4 induces p21waf1 expression and growth inhibition in human carcinoma cells.Cancer Res 1998;58:5656-5661.

56. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary K, Chiao PJ. The nuclear factor -kB RelA transcriptionfactor is constitutively activated in human pancreatic adenocarcinoma. Clin Cancer Res1999;5:119-127.

57. Kuniyasu H, Ellis L, Evans DB, Abbruzzese JL, Fenoglio CJ, Bucana CD, Cleary KR, Tahara E, Fidler IJ.Relative expression of E-Cadherin and type IV collagenase genes predicts disease outcome in patientswith resectable pancreatic carcinoma. Clin Cancer Res 1999;5:25-33.

58. Bold RJ, Charnsangavej C, Cleary KR, Jennings M, Madary A, Leach SD, Abbruzzese JL, Pisters PWT, LeeJE, Evans DB. Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic,intraoperative, and pathologic analysis. J Gastrointest Surg 1999;3:233-243.

59. Bold RJ, Hess KR, Pearson AS, Grau AM, Sinicrope FA, Jennings M, McConkey DJ, Bucana CD, ClearyKR, Chiao PJ, Abbruzzese JL, Evans DB. Prognostic factors in resectable pancreatic cancer: p53 andbcl-2. J Gastrointest Surg 1999;3:263-277.

60. Wang W, Abbruzzese JL, Evans DB, Chiao PJ. Overexpression of urokinase-type plasminogen activator inpancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene1999;18(32):4554-4563.

61. Ajani JA, Mansfield PF, Lynch PM, Pisters PW, Feig B, Dumas P, Evans DB, Raijman I, Hargraves K,Curley S, Ota DM. Enhanced Staging and all chemotherapy preoperatively in patients with potentiallyresectable gastric carcinoma. J Clin Oncol 1999;17;2403-2411.

62. Fleming JB, Lee JE, Bouvet M, Schultz PN, Sherman SI, Sellin RV, Friend KE, Burgess MA, Cote GJ,Gagel RF, Evans DB. Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg1999;230:697-707.

63. Dackiw APB, Cote GJ, Fleming JB, Schultz PN, Stanford P, Vassilopoulou-Sellin R, Evans DB, Gagel RF,Lee JE. Screening for MEN 1 mutations in patients with atypical endocrine neoplasia. Surgery1999;126:1097-1104.

64. Chiao PJ, Hunt KK, Grau AM, Abramian A, Fleming J, Zhang W, Breslin T, Abbruzzese JL, Evans DB.Tumor suppressor gene Smad4/DPC4, its downstream target genes, and regulation of cell cycle. AnnNew York Academy of Sciences 1999;880:31-37.

65. Pisters PWT, Hudec WA, Lee JE, Raijman I, Lahoti S, Janjan NA, Rich TA, Crane CH, Lenzi R, Wolff RA,Abbruzzese JL, Evans DB. Preoperative chemoradiation for patients with pancreatic cancer: toxicityof endobiliary stents. J Clin Oncol 2000;18:860-867.

66. Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, Evans DB, Abbruzzese JL, HicklinDJ, Radinsky R. Epidermal growth factor receptor blockade with C225 plus gemcitabine results inregression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenicmechanisms. Clin Cancer Res 2000;6:1936-1948.

67. Dackiw APB, Sussman JJ, Fritsche HA, Delpassand ES, Stanford P, Hoff AO, Gagel RF, Evans DB, Lee JE.Relative contributions of Technetium Tc 99m sestamibi scintigraphy, intraoperative gamma probedetection and the rapid parathyroid hormone assay to the surgical management ofhyperparathyroidism. Arch Surg 2000;135:550-557.

68. Ehlers RA, Kim S, Zhang Y, Ethridge RT, Murrilo C, Hellmich MR, Evans DB, Townsend CM, Evers BM.Gut peptide receptor expression in human pancreatic cancers. Ann Surg 2000;231:838-848.

69. Pearson AS, Chiao P, Zhang L, Zhang W, Larry L, Katz RL, Evans DB, Abbruzzese JL. The detection oftelomerase activity in patients with adenocarcinoma of the pancreas by fine needle aspiration. Int JOncol 2000;2:381-385.

70. Gocke CD, Benko FA, Kopreski MS, Evans DB. Enrichment methods for mutation detection. Ann NewYork Academy of Sciences 2000;906:31-38.

71. Porter GA, Pisters PWT, Mansyur C, Bisanz A, Reyna K, Stanford P, Lee JE, Evans DB. Cost andutilization impact of a clinical pathway for patients undergoing pancreaticoduodenectomy. Ann SurgOncol 2000;7:484-489.

72. Barnett CC, Varma DG, El-Naggar AK, Dackiw APB, Porter GA, Pearson AS, Kudelka AP, Gagel RF, Evans DB

18 / 41

, Lee JE. Limitations of size as a criterion in the evaluation of adrenal tumors. Surgery2000;128:973-983.

73. Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, Wolff RA, Abbruzzese JL, JanjanNA, Crane CH, Vauthey JN, Lee JE, Pisters PWT, Evans DB. Neoadjuvant chemoradiation foradenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol2001;8:123-132.

74. Pisters PWT, Lee JE, Vauthey JN, Charnsangavej C, Evans DB. Laparoscopy in the staging of pancreaticcancer. Brit J Surg 2001;88:325-337.

75. Pisters PWT, Hudec WA, Hess KR, Lee JE, Vauthey JN, Lahoti S, Raijman I, Evans DB. Effect ofpreoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300consecutive patients. Ann Surg 2001;234:47-55.

76. Wolff RA, Evans DB, Gravel DM, Lenzi R, Pisters PWT, Lee JE, Janjan NA, Charnsangavej C, AbbruzzeseJL. Phase I trial of gemcitabine combined with radiation for the treatment of locally advancedpancreatic adenocarcinoma. Clin Cancer Res 2001;7:2246-2253.

77. Crane CH, Janjan NA, Evans DB, Wolff RA, Ballo MT, Milas L, Mason K, Charnsangavej C, Pisters PWT,Lee JE, Lenzi R, Vauthey NJ, Wong A, Phan T, Nguyen Q, Abbruzzese JL. Toxicity and efficacy ofconcurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatology2001;29:9-18.

78. Esnaola NF, Cantor SB, Sherman SI, Lee JE, Evans DB. Optimal treatment strategy in patients withpapillary thyroid cancer: a decision analysis. Surgery 2001;130:921-930.

79. Solorzano CC, Lee JE, Pisters PWT, Vauthey JN, Ayers GD, Jean M, Gagel RF, Ajani JA, Wolff RA, EvansDB. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of163 patients. Surgery 2001;130:1078-1085.

80. Lenert JT, Barnett CC, Kudelka AP, Sellin RV, Gagel RF, Prieto VG, Skibber JM, Ross MI, Pisters PWT,Curley SA, Evans DB, Lee JE. Evaluation and surgical resection of adrenal masses in patients with ahistory of extra-adrenal malignancy. Surgery 2001;130:1060-1067.

81. Crane CH, Antolack J, Rosen I, Forester K, Evans DB, Abbruzzese, JL, Janjan NA, Charnsangavej C,Pisters PWT, Lenzi, R, Papagikos MA, Wolff RA: Phase I study of concomitant gemcitabine andIMRT for patients with unresectable adenocarcinoma of the pancreatic head. Int J Gastrointest Cancer2001;30:123-32.

82. Li D, Firozi PF, Zhang W, Shen J, DiGiovanni J, Serrine L, Evans D, Friess H, Hassan M, Abbruzzese JL.DNA adducts, genetic polymorphisms, and K-ras mutation in human pancreatic cancer. Mutation Res.2002. 513(1-2):37-48.

83. Crane CH, Abbruzzese JL, Evans DB, Wolff RA, Ballo MT, Delclos M, Milas L, Mason K, CharnsangavejC, Pisters PW, Lee JE, Lenzi R, Vauthey JN, Wong AB, Phan T, Nguyen Q, Janjan NA: Is thetherapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-basedchemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys2002;52(5):1293-302.

84. Pisters PWT, Wolff RA, Janjan NA, Cleary KR, Charnsangavej C, Crane C, Lenzi R, Vauthey JN, Lee JE,Abbruzzese JL, Evans DB. Preoperative paclitaxel and concurrent rapid-fractionation radiation forresectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. JClin Oncol 2002;20:2537-2544.

85. Kouvaraki MA, Lee JE, Shapiro SE, Gagel RF, Sherman SI, Sellin RV, Cote GJ, Evans DB. Genotype-Phenotype Analysis in Multiple Endocrine Neoplasia Type 1. Arch Surg 2002;137:641-647.

86. Lenzi R, Yalcin S, Evans DB, Abbruzzese JL. Phase II study of docetaxel in patients with pancreatic cancerpreviously untreated with cytotoxic chemotherapy. Cancer Invest 2002;20:464-472.

87. Dong QG, Sclabas GM, Fujioka S, Schmidt C, Peng B, Wu T, Tsao MS, Evans DB, Abbruzzese JL,McDonnell TJ, Chiao PJ, The function of multiple I kappa B:NF-kappa B complexes in the resistanceof cancer cells to Taxol-induced apoptosis. Oncogene 2002:21;6510-9.

88. Peng B, Fleming JB, Breslin T, Grau AM, Fojioka S, Abbruzzese JL, Evans DB, Ayers GD, Wathen K, WuT, Robertson KD, Chiao PJ. Suppression of tumorigenesis and induction of p15ink4b bySMAD4/DPC4 in human pancreatic cancer cells. Clin Cancer Res 2002;8:3628-3638.

89. Royal RE, Delpassand ES, Shapiro SE, Fritsche HA, Vassilopoulou-Sellin R, Sherman SI, Gagel RF, EvansDB, Lee JE. Improving the yield of preoperative parathyroid localization: sestamibi imaging afterthyroid suppression. Surgery 2002;132:968-975.

90. Bilimoria MM, Cormier JN, Mun Y, Lee JE, Evans DB Pisters PWT. Pancreatic leak after leftpancreatectomy is reduced following main pancreatic duct ligation. Brit J Surg 2003;90:190-196.

19 / 41

91. Sclabas GM, Fujioka S, Schmidt C, Fan Z, Evans DB, Chiao PJ. Restoring apoptosis in pancreatic cancercells by targeting the NF-kB signalling pathway with the anti-EGFR antibody IMC-C225. JGastrointest Surg 2003;7:37-43.

92. Raut CP, Grau AM, Staerkel GA, Kaw M, Tamm EP, Wolff RA, Vauthey JN, Lee JE, Pisters PWT, EvansDB. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration in patients withpresumed pancreatic cancer. J Gastrointest Surg 2003;7:118-128.

93. Fujioka S, Sclabas GM, Schmidt C, Frederick WA, Dong QG, Abbruzzese JL, Evans DB, Baker C, ChiaoPJ. Function of nuclear factor ?B in pancreatic cancer metastasis. Clin Cancer Res. 2003;9:346-354.

94. Abdalla EK, Barnett CC, Pisters PWT, Cleary KR, Evans DB, Feig BW, Mansfield PF. Subaquaticlaparoscopy for staging of intraabdominal malignancy. J Am Coll Surg. 2003;196:155-158.

95. Li D, Zhu JJ, Firozi PF, Abbruzzese JL, Evans DB, Cleary K, Friess H, Sen S. Overexpression of oncogenicSTK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 2003;9:991-997.

96. Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, Sherman SI, Gagel RF, Lee JE, Evans DB.Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg2003;138:409-416.

97. Fujioka S, Sclabas GM, Schmidt C, Niu J, Frederick WA, Dong QG, Abbruzzese JL, Evans DB, Baker C,Chiao PJ. Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppressestumorigenesis. Oncogene 2003;22:1365-1370.

98. Solorzano CC, Hwang R, Baker CH, Bucana CD, Pisters PWT, Evans DB, Killion JJ, Fidler IJ.Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabineinduces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreaticcarcinoma implanted orthotopically in nude mice. Clin Cancer Res 2003;9:1858-1867.

99. Tamm EP, Silverman PM, Charnsangavej C, Evans DB. Diagnosis, staging, and surveillance of pancreaticcancer. Am J Roentgenol 2003;180:1311-23.

100. Parikh AA, Liu WB, Fan F, Stoeltzing O, Reinmuth N, Bruns CJ, Bucana CD, Evans DB, Ellis LM.Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 byepidermal growth factor in human pancreatic carcinoma. Cancer 2003;98:720-729.

101. Stoeltzing O, Liu W, Reinmuth N, Fan F, Parikh AA, Bucana CD, Evans DB, Semenza GL, Ellis LM.Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis byan insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol.2003;163:1001-11.

102. Shapiro SE, Cote GC, Lee JE, Gagel RF, Evans DB. The role of genetics in the surgical management offamilial endocrinopathy syndromes. J Amer Col of Surg. 2003;197:818-831.

103. Schmidt C, Peng B, Zhongkui L, Sclabas GM, Fujioka S, Niu J, Schmidt-Supprian M, Evans DB,Abbruzzese JL, Chiao PJ. Mechanisms of proinflammatory cytokine-induced biphasic NF-kappa Bactivation. Mol Cell 2003;12:1-20.

104. Pederson LC, Shapiro SE, Fritsche HA, Delpassand ES, Gagel RF, Sherman SI, Vassilopoulou-Sellin R, Evans DB, Lee JE. Maximizing parathyroid preservation in central neck surgery: potential role forintraoperative gamma probe identification of normal parathyroid glands. Am J Surg2003;186:711-717.

105. Sclabas GM, Staerkel GA, Shapiro SE, Fornage BD, Sherman SI, Sellin RV, Lee JE, Evans DB. Fine-needle aspiration of the thyroid: correlation with histopathology in a contemporary series of 240patients. Am J Surg 2003;186:702-710.

106. Kouvaraki MA, Shapiro SE, Fornage BD, Ediken-Monro BS, Sherman SI, Vassilopoulou-Sellin R, Lee JE, Evans DB. Role of preoperative ultrasonography in the surgical management of patients with thyroidcancer. Surgery 2003;134:946-954.

107. Yen TWF, Shapiro SE, Gagel RF, Sherman SI, Lee JE, Evans DB. Medullary thyroid carcinoma: results ofa standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery2003;134:890-899.

108. Hwang RF, Yokoi K, Bucana CD, Tsan R, Killion JJ, Evans DB, Fidler IJ. Inhibition of platelet-derivedgrowth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of humanpancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 2003;9:6534-6544

109. Yip L, Lee JE, Shapiro SE, Waguespack SG, Sherman SI, Hoff AO, Gagel RF, Arens JF, Evans DB.Surgical management of hereditary pheochromocytoma. J Am Coll Surg 2004;198:525-535.

110. Recine M, Kaw M, Evans DB, Krishnamurthy S. Fine-needle aspiration cytology of mucinous tumors ofthe pancreas. Cancer. 2004;25;102:92-9.

20 / 41

111. Fujioka S, Schmidt C, Sclabas GM, Li Z, Pelicano H, Peng B, Yao A, Niu J, Zhang W, Evans DB,Abbruzzese JL, Huang P, Chiao PJ. Stabilization of p53 is a novel mechanism for proapoptoticfunction of NF-kappa B. J Biol Chem. 2004;279(26):27549-59.

112. Li Z, Sclabas GM, Peng B, Hess HR, Abbruzzese JL, Evans DB, Chiao PJ. Overexpression of synuclein-gamma in pancreatic adenocarcinoma. Cancer. 2004;101(1):58-65.

113. Jimenez C, Dang GT, Schultz PN, El-Naggar A, Shapiro S, Barnes EA, Evans DB, Vassilopoulou-Sellin R,Gagel RF, Cote GJ, Hoff AO. A novel point mutation of the RET protooncogene involving the secondintracellular tyrosine kinase domain in a family with medullary thyroid carcinoma. J Clin EndocrinolMetab. 2004;89(7):3521-6.

114. Busaidy NL, Jimenez C, Habra MA, Schultz PN, El-Naggar AK, Clayman GL, Asper JA, Diaz EM, EvansDB, Gagel RF, Garden A, Hoff AO, Lee JE, Morrison WH, Rosenthal DI, Sherman SI, Sturgis EM,Waguespack SG, Weber RS, Wirfel K, Vassilopoulou-Sellin R. Parathyroid carcinoma: a 22 yearexperience. .Head Neck. 2004;26(8):716-26.

115. Jimenez C, Habra MA, Huang SC, El-Naggar A, Shapiro SE, Evans DB, Cote G, Gagel RF.Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of theRET protooncogene 891 germline mutation. J Clin Endocrinol Metab. 2004;89(8):4142-5.

116. Fujioka S, Niu J, Schmidt C, Sclabas GM, Pend B, Uwagawa T, Li Z, Evans DB, Abbruzzese JL, Chiao PJ.NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity.Mol Cell Biol. 2004;17:7806-19.

117. Tseng JF, Raut CP, Lee JE, Pisters PWT, Vauthey JN, Abdalla EK, Gomez HF, Sun CC, Crane CH, WolffRA, Evans DB. Pancreaticoduodenectomy with vascular resection: margin status and survivalduration. J Gastrointest Surg. 2004;8(8):935-950.

118. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC. Fluorouracil, doxorubicin, andstreptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrinecarcinomas. J Clin Oncol. 2004;22(23):4710-9.

119. Kouvaraki MA, Lee JE, Shapiro SE, Sherman SI, Evans DB. Preventable reoperations for persistent andrecurrent papillary thyroid carcinoma. Surgery 2004;136(6):1183-91.

120. Sclabas GM, Fujioka S, Schmidt C, Li Z, Frederick WA, Yang W, Yokoi K, Evans DB, Abbruzzese JL,Hess KR, Zhang W, Fidler IJ, Chiao PJ. Overexpression of tropomysin-related kinase B in metastatichuman pancreatic cancer cells. Clin Cancer Res. 2005;11:440-9.

121. Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS, Gallick GE. HIF-1alpha, STAT3,CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependenthypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene.2005;24(19):3110-20.

122. Lambert LA, Shapiro SE, Lee JE, Perrier ND, Truong M, Wallace MJ, Hoff AO, Gagel RF, Evans DB.Surgical treatment of hyperparathyroidism in patients with multiple endocrine neoplasia type 1. ArchSurg. 2005;140(4):374-82.

123. Sclabas GM, Uwagawa T, Schmidt C, Hess KR, Evans DB, Abbruzzese JL, Chiao PJ. Nuclear factor kappaB activation is a potential target for preventing pancreatic carcinoma by aspirin. Cancer.2005;103(12):2485-90.

124. Gray MJ, Wey JS, Belcheva A, McCarty MF, Trevino JG, Evans DB, Ellis LM, Gallick GE. Neuropilin-1suppresses tumorigenic properties in a human pancreatic adenocarcinoma cell line lacking neuropilin-1coreceptors. Cancer Res. 2005;65(9):3664-70.

125. Li D, Ahmed M, Li Y, Jiao L, Chou TH, Wolff RA, Lenzi R, Evans DB, Bondy ML, Pisters PWT,Abbruzzese JL, Hassan NM. 5,10-Methylenetetrahydrofolate reductase polymorphisms and the risk ofpancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(6):1470-6.

126. Wey JS, Fan F, Gray MJ, Bauer TW, McCarty MF, Somcio R, Liu W, Evans DB, Wu Y, Hicklin DJ, EllisLM. Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreaticcarcinoma cell lines. Cancer. 2005;104(2):427-38.

127. Wey JS, Gray MJ, Fan F, Belcheva A, McCarty MF, Stoeltzing O, Somcio R, Liu W, Evans DB, KlagsbrunM, Gallick GE, Ellis LM. Overexpression of neuropilin-1 promotes constitutive MAPK signalling andchemoresistance in pancreatic cancer cells. Br J Cancer. 2005;93(2):233-41.

128. Pawlik TM, Abdalla EK, Barnett CC, Ahmad SA, Cleary KR, Vauthey JN, Lee JE, Evans DB, PistersPWT. Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer. ArchSurg. 2005;140(6):584-9; discussion 589-91.

129. Kouvaraki MA, Shapiro SE, MS, Perrier ND Cote GJ, Gagel RF, Hoff AO, Sherman SI, Lee JE, Evans DB.

21 / 41

RET Proto-Oncogene: A review and update of genotype-phenotype correlations in hereditarymedullary thyroid cancer and associated endocrine tumors. Thyroid. 2005;15(6):531-44.

130. Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB,Boyd DD, Mazar AP, Ellis LM. Targeting of urokinase plasminogen activator receptor in humanpancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migrationand invasion and orthotopic tumor growth in mice. Cancer Res. 2005;65(17):7775-81.

131. Mullen JT, Lee JH, Gomez HF, Ross WA, Fukami N, Wolff RA, Abdalla EK, Vauthey JN, Lee JE, PistersPWT, Evans DB. Pancreaticoduodenectomy after placement of endobiliary metal stents. J GastrointestSurg. 2005;9(8):1094-1105.

132. Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, Doubilet PM, Evans DB,Goellner JR, Hay ID, Hertzberg BS, Intenzo CM, Jeffrey RB, Langer JE, Larsen PR, Mandel SJ,Middleton WD, Reading CC, Sherman SI, Tessler FN. Management of thyroid nodules detected at US:Society of Radiologists in Ultrasound consensus conference statement. Radiology. 2005;237:794-800.

133. Gonzalez RJ, Shapiro S, Sarlis N, Vassilopoulou-Sellin R, Perrier ND, Evans DB, Lee, JE. Laparoscopicresection of adrenal cortical carcinoma: A cautionary note. Surgery 2005;138:1078-1086.

134. Mullen JT, Wang H, Yao JC, Lee JH, Perrier ND, Pisters PWT, Lee JE, Evans DB. Carcinoid tumors of theduodenum. Surgery 2005;138:971-978.

135. Li D, Frazier M, Evans DB, Hess KR, Crane CH, Jiao L, Abbruzzese JL. Single nucleotide polymorphismsof RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J ClinOncol. 2006;24(11):1720-8.

136. Crane CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HO, Ho L, Evans DB, Tamm EP, Ng C, Pisters PW,Charnsangavej C, Delclos ME, O'Reilly M, Lee JE, Wolff RA. Phase I trial evaluating the safety ofbevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. JClin Oncol. 2006;24(7):1145-51.

137. Raut CP, Cleary KR, Staerkel GA, Abbruzzese JL, Wolff RA, Lee JH, Vauthey JN, Lee JE, Pisters PWT, Evans DB. Intraductal papillary mucinous neoplasms of the pancreas: effect of invasion and pancreaticmargin status on recurrence and survival. Ann Surg Oncol. 2006;4:582-94.

138. Li D, Liu H, Jiao L, Chang DZ, Beinart G, Wolff RA, Evans DB, Hassan MM, Abbruzzese JL. Significanteffect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival.Cancer Res. 2006;66(6):3323-30.

139. Delman KA, Shapiro SE, Jonasch EW, Lee JE, Curley SA, Evans DB, Perrier ND. Abdominal viscerallesions in von hippel-lindau disease: incidence and clinical behavior of pancreatic and adrenal lesionsat a single center. World J Surg. 2006;30(5):665-9.

140. Kouvaraki MA, Greer M, Sharma S, Beery D, Armand R, Lee JE, Evans DB, Perrier ND. Indications foroperative intervention in patients with asymptomatic primary hyperparathyroidism: practice patterns ofendocrine surgery. Surgery. 2006;139(4):527-34.

141. Kouvaraki MA, Shapiro SE, Cote GJ, Lee JE, Yao JC, Waguespack SG, Gagel RF, Evans DB, Perrier ND.Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg.2006;30(5):643-53.

142. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, Lee JE, Pisters PWT, EvansDB, Wolff RA. Borderline resectable pancreatic cancer: definitions, management, and role ofpreoperative therapy. Ann Surg Oncol. 2006;13(8):1035-46.

143. Bauer TW, Somcio RJ, Fan F, Liu W, Johnson M, Lesslie DP, Evans DB, Gallick GE, Ellis LM.Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion ofhuman pancreatic carcinoma cells. Mol Cancer Ther. 2006;5(7):1676-82.

144. Kouvaraki MA, Korapati AL, Rassidakis GZ, Tian L, Zhang Q, Chiao PJ, Ho L, Evans DB, Claret FX.Potential Role of Jun Activation Domain-Binding Protein 1 as a Negative Regulator of p27kip1 inPancreatic Adenocarcinoma. Cancer Res. 2006;66(17):8581-9.

145. Das P, Wolff RA, Abbruzzese JL, Varadhachary GR, Evans DB, Vauthey JN, Baschnagel A, Delclos ME,Krishnan S, Janjan NA, Crane CH. Concurrent capecitabine and upper abdominal radiation therapy iswell tolerated. Radiat Oncol. 2006;1(1):41.

146. Trevino JG, Gray MJ, Nawrocki ST, Summy JM, Lesslie DP, Evans DB, Sawyer TK, Shakespeare WC,Watowich SS, Chiao PJ, McConkey DJ, Gallick GE. Src activation of Stat3 is an independentrequirement from NF-kappaB activation for constitutive IL-8 expression in human pancreaticadenocarcinoma cells. Angiogenesis. 2006;9(2):101-10.

147. Krishnan S, Rena V, Janjan NA, Gould MS, Das P, Delclos ME, Palla S, Guha S, Varadhachary G, EvansDB, Wolff RA, Crane CH. Prognostic factors in patients with unresectable locally advanced pancreatic

22 / 41

adenocarcinoma treated with chemoradiation. Cancer. 2006;107(11):2589-96.148. Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, Cronan JJ, Doubilet PM,

Evans DB, Goellner JR, Hay ID, Hertzberg BS, Intenzo CM, Jeffrey RB, Langer JE, Larsen PR,Mandel SJ, Middleton WD, Reading CC, Sherman SI, Tessler FN. Management of thyroid nodulesdetected at US: Society of Radiologists in Ultrasound consensus conference statement. Ultrasound Q.2006;22(4):231-8.

149. Rodgers SE, Hunter GJ, Hamberg LM, Schellingerhout D, Doherty DB, Ayers GD, Shapiro SE, EdeikenBS, Truong MT, Evans DB, Lee JE, Perrier ND. Improved preoperative planning for directedparathyroidectomy with 4-dimensional computed tomography. Surgery. 2006:140(6):932-41.

150. Tamm EP, Loyer EM, Faria S, Raut CP, Evans DB, Wolff RA, Crane CH, Dubrow RA, Charnsangavej C.Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiationtherapy. Abdom Imaging. 2006, Sep 12.

151. Jiao L, Zhu J, Hassan MM, Evans DB, Abbruzzese JL, Li D. K-ras mutation and p16 and preproenkephalinpromoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarettesmoking. Pancreas. 2007:34(1);55-62.

152. Jiao L, Hassan MM, Bondy ML, Abbruzzese JL, Evans DB, Li D. The XPD Asp(312)Asn andLys(751)Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk. Cancer Lett.2007:8;245(1-2);61-8.

153. Li D, Li Y, Jiao L, Chang DZ, Beinart G, Wolff RA, Evans DB, Hassan MM, Abbruzzese JL. Effects ofbase excision repair gene polymorphisms on pancreatic cancer survival. Int J Cancer2007;120(8):1748-54.

154. Jiao L, Bondy ML, Hassan MM, Chang DZ, Abbruzzese JL, Evans DB, Smolensky MH, Li D. GlutathioneS-transferase gene polymorphisms and risk and survival of pancreatic cancer. Cancer2007;109(5):840-8.

155. Baruch AC, Wang H, Staerkel GA, Evans DB, Hwang RF, Krishnamurthy S. Immunocytochemical studyof the expression of mesothelin in fine-needle aspiration biopsy specimens of pancreaticadenocarcinoma. Diagn Cytopathol. 2007;35(3):143-7.

156. Camp ER, Yang A, Gray MJ, Fan F, Hamilton SR, Evans DB, Hooper AT, Pereira DS, Hicklin DJ, EllisLM. Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation asa target. Cancer. 2007;109(6):1030-1039.

157. Aloia TE, Lee JE, Vauthey JN, Abdalla EK, Wolff RA, Varadhachary GR, Abbruzzese JL, Crane CH, Evans DB, Pisters PW. Delayed recovery after pancreaticoduodenectomy: a major factor impairing thedelivery of adjuvant therapy? J Am Coll Surg. 2007;204(3):347-55.

158. Zhang J, Jia Z, Li Q, Wang L, Rashid A, Zhu Z, Evans DB, Vauthey JN, Xie K, Yao JC. Elevatedexpression of vascular endothelial growth factor correlates with increased angiogenesis and decreasedprogression-free survival among patients with low-grade neuroendocrine tumors. Cancer.2007;109(8):1478-1486.

159. Tseng JF, Lee JE, Pisters PWT, Wang H, Gomez HF, Sun CC, Evans DB. The learning curve in pancreaticsurgery. Surgery. 2007;(5):694-701.

160. Uwagawa T, Li Z, Chang Z, Xia O, Peng B, Sclabas GM, Ishiyama S, Hung MC, Evans DB, AbbruzzeseJL, Chiao PJ. Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death.Cancer. 2007;109(10):2142-53.

161. Li D, Day RS, Bondy ML, Sinha R, Nguyen NT, Evans DB, Abbruzzese JL, Hassan MM. Dietary mutagenexposure and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(4):655-61.

162. Balachandran A, Darden DL, Tamm EP, Faria SC, Evans DB, Charnsangavej C. Arterial variants inpancreatic adenocarcinoma. Abdom Imaging. 2007; April 10.

163. Chen J, Li D, Wei C, Sen S, Killary AM, Amos CL, Evans DB, Abbruzzese JL, Frazier ML. Aurora-A andp16 polymorphisms contribute to an earlier age at diagnosis of pancreatic cancer in Caucasians. ClinCancer Res. 2007;13(10):3100-3104.

164. Hassan MM, Abbruzzese JL, Bondy ML, Wolff RA, Vauthey JN, Pisters PW, Evans DB, Khan R, Lenzi R,Jiao L, Li D. Passive smoking and the use of noncigarette tobacco products in association with risk forpancreatic cancer: A case-control study. Cancer. 2007;109(12):2547-56.

165. Krishnan S, Rana V, Janjan NA, Varadhachary GR, Abbruzzese JL, Das P, Delclos ME, Gould MS, EvansDB, Wolff RA, Crane CH. Induction chemotherapy selects patients with locally advanced,unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer.2007;110(1):47-55.

166. Reyes-Gibby CC, Chan W, Abbruzzese JL, Xiong HO, Ho L, Evans DB, Varadhachary G, Bhat S, Wolff

23 / 41

RA, Crane C. Patterns of Self-Reported Symptoms in Pancreatic Cancer Patients ReceivingChemoradiation. J Pain Symptom Manage. 2007;34(3):244-52.

167. Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CC, Hwang R, Vauthey JN, Abdalla EK, Lee JE,Pisters PWT, Evans DB. Impact of Resection Status on Pattern of Failure and Survival afterPancreaticoduodenectomy for Pancreatic Adenocarcinoma. Ann Surg. 2007;246(1):52-60.

168. Xie X, Xia W, Li Z, Kuo H-P, Liu Y, Li Z, Ding Q, Zhang S, Spohn W, Yang Y, Wei Y, Lang J-Y, EvansDB, Chiao PJ, Abbruzzese JL, Hung M-C. Targeted Expression of BikDD Eradicates PancreaticTumors in Noninvasive Imaging Models. Cancer Cell. 2007;12(1):52-65.

169. Mittendorf EA, Wang X, Perrier ND, Francis AM, Edeiken BS, Shapiro SE, Lee JE, Evans DB. The follow-up of patients with papillary thyroid cancer: in search of the optimal algorithm. J Am Coll Surg.2007;205(2):239-47.

170. Mittendorf EA, Wefel JS, Meyers CA, Doherty D, Shapiro SE, Lee JE, Evans DB, Perrier ND.Improvement of sleep disturbance and neurocognitive function after parathyroidectomy in patientswith primary hyperparathyroidism. Endocr Pract. 2007;13(4):338-44.

171. Tamm EP, Loyer EM, Faria SC, Evans DB, Wolff RA, Charnsangavej C. Retrospective analysis of dual-phase MDCT and follow-up EUS/EUS-FNA in the diagnosis of pancreatic cancer. Abdom Imaging.2007;32(5):660-7.

172. Yao JC, Eisner MP, Leary C, Dagohoy C, Phan A, Rashid A, Hassan M, Evans DB. Population-basedstudy of islet cell carcinoma. Ann Surg Oncol. 2007;14(12):3492-500.

173. Hassan MM, Bondy ML, Wolff RA, Abbruzzese JL, Vauthey JN, Pisters PW, Evans DB, Khan R, ChouTH, Lenzi R, Jiao L, Li D. Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol.2007;102(12):2696-707.

174. Gonzalez RJ, Tamm EP, Ng C, Phan AT, Vassilopoulou-Sellin R, Perrier ND, Evans DB, Lee JE.Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. Surgery.2007;142(6):867-75.

175. Schwartz DL, Rana V, Shaw S, Yazbeck C, Ang KK, Morrison WH, Rosenthal DI, Hoff A, Evans DB,Clayman GL, Garden AS, Sherman SI. Postoperative radiotherapy for advanced medullary thyroidcancer--local disease control in the modern era. Head Neck. 2008;30(7):883-8.

176. Wray CW, Rich TA, Waguespack SG, Lee JE, Perrier ND, Evans DB. Failure to Recognize MultipleEndocrine Neoplasia 2B: more common than we think? Ann Surg Oncol. 2008;15(1):293-301.

177. Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, Ji B, Evans DB, Logsdon CD.Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res.2008;68(3):918-26.

178. Krishnan S, Rana V, Evans DB, Varadhachary G, Das P, Bhatia S, Delclos ME, Janjan NA, Wolff RA,Crane CH, Pisters PW. Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla ofvater. Int J Radiat Oncol Biol Phys. 2008;70(3):735-43.

179. Jiao L, Hassan MM, Bondy ML, Wolff RA, Evans DB, Abbruzzese JL, Li D. XRCC2 and XRCC3 GenePolymorphism and Risk of Pancreatic Cancer. Am J Gastroenterol. 2008;103(2):360-7.

180. Guerrero MA, Evans DB, Lee JE, Bao R, Bereket A, Gantela S, Griffin GD, Perrier ND. Viability ofCryopreserved Parathyroid Tissue: When Is Continued Storage versus Disposal Indicated? World JSurg. 2008;32(5):836-9.

181. Katz MHG, Hwang RF, Fleming JB, Evans DB. TNM staging of pancreatic adenocarcinoma. Tumor-node-metastasis staging of pancreatic adenocarcinoma. CA Cancer J Clin. 2008;58(2):111-25.

182. Hwang R, Wang H, Lara A, Gomez H, Pomes K, Chang T, Sieffert S, Ram S, Zimmerman S, Lee JH,Pisters PWT, Tamm EP, Abbruzzese JL, Evans DB. Development of an integrated biospecimen bankand multidisciplinary clinical database for pancreatic cancer. Ann Surg Oncol. 2008;15(5):1356-66.

183. Okazaki T, Jiao L, Chang P, Evans DB, Abbruzzese JL, Li D. Single-Nucleotide Polymorphisms of DNADamage Response Genes Are Associated with Overall Survival in Patients with Pancreatic Cancer.Clin Cancer Res. 2008;14(7):2042-2048.

184. Ross WA, Wasan SM, Evans DB, Wolff RA, Trapani LV, Staerkel GA, Prindville T, Lee JH. CombinedEUS with FNA and ERCP for the evaluation of patients with obstructive jaundice from presumedpancreatic malignancy. Gastrointest Endosc. 2008;68(3):461-6.

185. Mortenson MM, Katz MH, Tamm EP, Bhutani MS, Wang H, Evans DB, Fleming JB. Current diagnosisand management of unusual pancreatic tumors. Am J Surg. 2008;196(1):100-13.

186. Vengrove MA, Schimmel M, Atkinson BF, Evans D, LiVolsi VA. Invasive cervical thymomamasquerading as a solitary thyroid nodule. Report of a case studied by fine needle aspiration. Acta

24 / 41

Cytol. 1991 Jul-Aug;35(4):431-3. 187. Katz MHG, Pisters PWT, Evans DB, Sun CC, Lee JE, Fleming JB, Vauthey JN, Abdalla EK, Crane CH,

Wolff RA, Varadhachary GR, Hwang RF. Borderline resectable pancreatic cancer: the importance ofthis emerging stage of disease. J Am Coll Surg. 2008;206(5):833-46; discussion 846-8.

188. Raut CP, Evans DB. Variability in reporting resection margin status in pancreatic cancer Annals ofSurgery. April 2008;247(4):717-718.

189. Mortenson MM, Evans DB, Lee JE, Hunter GJ, Shellingerhout D, Vu T, Edeiken BS, Feng L, Perrier ND.Parathyroid exploration in the reoperative neck: improved preoperative localization with 4D-computedtomography. J Am Coll Surg. 2008 May;206(5):888-95; discussion 895-6.

190. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, RashidA, Evans DB. One hundred years after "carcinoid": epidemiology of and prognostic factors forneuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063-72.

191. Philip M, Guerrero MA, Evans DB, Hunter GJ, Edeiken-Monroe BS, Vu T, Perrier ND. Efficacy of 4D-CTPreoperative Localization in 2 Patients with MEN 2A. J Surg Educ. 2008;65(3):182-5.

192. Monroe DP, Edeiken-Monroe BS, Lee JE, Evans DB, Perrier ND. Impact of preoperative thyroidultrasonography on the surgical management of primary hyperparathyroidism. Br J Surg.2008;95(8):957-960.

193. Katz MHG, Mortenson M, Wang H, Hwang R, Tamm EP, Staerkel G, Lee JH, Evans DB, Fleming JB.Diagnosis and management of cystic neoplasms of the pancreas: an evidence-based approach. J AmColl Surg. 2008;207(1):106-20.

194. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PWT, Vauthey JN, Wang H, Cleary KR,Staerkel GA, Charnsangavej C, Lano EA, Ho L, Lenzi R, Abbruzzese JL, Wolff RA. Preoperativegemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.J Clin Oncol. 2008;26(21):3496-502.

195. Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PWT, Vauthey JN, Abdalla E, Wang H,Staerkel GA, Lee JH, Ross WA, Tamm EP, Bhosale PR, Balachandran A, Krishnan S, Das P,Abbruzzese JL, Evans DB. Preoperative gemcitabine and cisplatin followed by gemcitabine-basedchemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol.2008;26(21):3487-95.

196. Weston BR, Ross WA, Wolff RA, Evans DB, Lee JE, Wang X, Xiao LC, Lee JH. Rate of bilirubinregression after stenting in malignant biliary obstruction for the initiation of chemotherapy: how soonshould we repeat endoscopic retrograde cholangiopancreatography? Cancer. 2008;112(11):2417-23.

197. Perrier ND, Kennamer DL, Bao R, Jimenez C, Grubbs EG, Lee JE, Evans DB. Posteriorretroperitoneoscopic adrenalectomy: preferred technique for removal of benign tumors and isolatedmetastases. Ann Surg. 2008;248(4):666-74.

198. Wolff RA, Varadhachary GR, Evans DB. Adjuvant therapy for adenocarcinoma of the pancreas: analysis ofreported trials and recommendations for future progress. Ann Surg Oncol. 2008;15(10):2773-86.

199. Borghero Y, Crane CH, Szklaruk J, Oyarzo M, Curley S, Pisters P, Evans D, Abdalla EK, Thomas MB,Das P, Wistuba II, Krishnan S, Vauthey JN. Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overallsurvival to patients with standard-risk treated with surgery alone. Ann Surg Oncol.2008;15(11):3147-56.

200. Overman MJ, Fogelman Dd, Al-Kali A, Crane CH, Evans D, Abdalla EK, Pisters P, Kopetz S, Eng C,Wolff RA. Aggressive combined modality therapy for recurrent colorectal cancer involving theduodenum and pancreas: a report of 5 cases. Clin Colorectal Cancer. 2008;7(5):338-42.

201. Liang JJ, Wang H, Rashid A, Tan TH, Hwang RF, Hamilton SR, Abbruzzese JL, Evans DB, Wang H.Expression of MAP4K4 Is Associated with Worse Prognosis in Patients with Stage II PancreaticDuctal Adenocarcinoma. Clin Cancer Res. 2008;14(21):7043-9

202. Grubbs EG, Rafeeq S, Jimenez C, Feng L, Lee JE, Evans DB, Perrier ND. Preoperative vitamin Dreplacement therapy in primary hyperparathyroidism: safe and beneficial? Surgery 2008; 144(6):852-8.

203. Katz MHG, Fleming JB, Pisters PWT, Lee JE, Evans DB. Anatomy of the superior mesenteric vein withspecial reference to the surgical management of first-order branch involvement atpancreaticoduodenectomy. Ann Surg. 2008;248(6):1098-102.

204. Chen J, Killary AM, Sen S, Amos CI, Evans DB, Abbruzzese JL, Frazier ML. Polymorphisms of p21 andp27 jointly contribute to an earlier age at diagnosis of pancreatic cancer. Cancer Lett.2008;272(1):32-9.

25 / 41

205. Borghero Y, Crane CH, Szklaruk J, Oyarzo M, Curley S, Pisters PW, Evans D, Abdalla EK, Thomas MB,Das P, Wistuba II, Krishnan S, Vauthey JN. Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overallsurvival to patients with standard-risk treated with surgery alone. Ann Surg Oncol. 2008Nov;15(11):3147-56.

206. Chen J, Li D, Killary AM, Sen S, Amos CI, Evans DB, Abbruzzese JL, Frazier ML. Polymorphisms ofp16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated withpreoperative chemoradiation. Ann Surg Oncol. 2009;16(2):431-9.

207. Wang H, Song X, Logsdon C, Zhou G, Evans DB, Abbruzzese JL, Hamilton SR, Tan TH, Wang H.Proteasome-mediated degradation and functions of hematopoietic progenitor kinase 1 in pancreaticcancer. Cancer Res. 2009;69(3):1063-70.

208. Santarpia L, Gagel RF, Sherman SI, Sarlis NJ, Evans DB, Hoff AO. Diabetes insipidus andpanhypopituitarism due to intrasellar metastasis from medullary thyroid cancer. Head Neck.2009;31(3):419-23.

209. Katz MHG, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, Varadhachary G, Abbruzzese JL, CraneCH, Krishnan S, Vauthey JN, Abdalla EK, Lee JE, Pisters PWT, Evans DB. Long-term survival aftermultidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol.2009;16(4):836-47.

210. Dong X, Jiao L, Li Y, Evans DB, Wang H, Hess KR, Abbruzzese JL, Li D. Significant associations ofmismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. J Clin Oncol.2009;27(10):1592-9.

211. Fleming JB, Gonzalez RJ, Petzel MQ, Lin E, Morris JS, Gomez H, Lee JE, Crane CH, Pisters PW, EvansDB. Influence of obesity on cancer-related outcomes after pancreatectomy to treat pancreaticadenocarcinoma. Arch Surg. 2009;144(3):216-21.

212. Callender GG, Grubbs EG, Vu T, Hofstetter WL, Fleming JB, Woodburn KL, Lee JE, Evans DB, PerrierND. The fallen one: the inferior parathyroid gland that descends into the mediastinum. J Am Coll Surg.2009;208(5):887-93.

213. Melisi D, Niu J, Chang Z, Xia Q, Peng B, Ishiyama S, Evans DB, Chiao PJ. Secreted interleukin-1 alphainduces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation of nuclearfactor-kappa B. Mol Cancer Res. 2009;7(5):624-33.

214. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, Francis GL, GagelRF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA Jr. Medullary thyroidcancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19(6):565-612.

215. Evans DB, Farnell MB, Lillemoe KD, Vollmer C Jr, Strasberg SM, Schulick RD. Surgical treatment ofresectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol.2009;16(7):1736-44.

216. Schwartz DL, Lobo MJ, Ang KK, Morrison WH, Rosenthal DI, Ahamad A, Evans DB, Clayman G,Sherman SI, Garden AS. Postoperative external beam radiotherapy for differentiated thyroid cancer:outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys. 2009;74(4):1083-91.

217. Shin SH, Holmes H, Bao R, Jimenez C, Kee SS, Potylchansky E, Lee JE, Evans DB, Perrier ND.Outpatient minimally invasive parathyroidectomy is safe for elderly patients. J Am Coll Surg.2009;208(6):1071-6.

218. Williams MD, Suliburk JW, Staerkel GA, Busaidy NL, Clayman GL, Evans DB, Perrier ND. Clinicalsignificance of distinguishing between follicular lesion and follicular neoplasm in thyroid fine-needleaspiration biopsy. Ann Surg Oncol. 2009;16(11):3146-53.

219. Li Z, Chang Z, Chiao LJ, Kang Y, Xia Q, Zhu C, Fleming JB, Evans DB, Chiao PJ. TrkBT1 induces livermetastasis of pancreatic cancer cells by sequestering Rho GDP dissociation inhibitor and promotingRhoA activation. Cancer Res. 2009;69(19):7851-9.

220. Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE. Generation of orthotopic andheterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc.2009;4(11):1670-80.

221. Perrier ND, Balachandran D, Wefel JS, Jimenez C, Busaidy N, Morris GS, Dong W, Jackson E, Weaver S,Gantela S, Evans DB, Grubbs EG, Lee JE. Prospective randomized controlled trial ofparathyroidectomy versus observation in patients with "asymptomatic" primary hyperparathyroidism.Surgery 2009;146(6):1116-22.

222. Marshall CL, Lee JE, Xing, Y, Perrier ND, Edeiken BS, Evans DB, Grubbs EG. Routine preoperativeultrasonography for papillary thyroid cancer: effects on cervical recurrence. Surgery

26 / 41

2009;146(6):1063-72.223. Grubbs EG, Callender GG, Xing Y, Perrier ND, Evans DB, Phan AT, Lee JE. Recurrence of adrenal

cortical carcinoma following resection: surgery alone can achieve results equal to surgery plusmitotane. Ann Surg Oncol. 2010 Jan;17(1):263-70.

224. Grubbs EG, Callender GG, Xing Y, Perrier ND, Evans DB, Phan AT, Lee JE. Recurrence of adrenalcortical carcinoma following resection: surgery alone can achieve results equal to surgery plusmitotane. Ann Surg Oncol. 2010;17(1):263-70.

225. Bhatia A, Rao A, Ang KK, Garden AS, Morrison WH, Rosenthal DI, Evans DB, Clayman G, Sherman SI,Schwartz DL. Anaplastic thyroid cancer: clinical outcomes with conformal radiotherapy. Head Neck.2010;32(7):829-36.

226. Katz MH, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, SunCC, Wang H, Crane CH, Lee JH, Tamm EP, Abbruzzese JL, Evans DB. Serum CA 19-9 as a Markerof Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated withNeoadjuvant Chemoradiation. Ann Surg Oncol. 2010;17(7):1794-801.

227. Morris GS, Grubbs EG, Hearon CM, Gantela S, Lee JE, Evans DB, Holmes HM, Busaidy NL, Jimenez C,Perrier ND. Parathyroidectomy improves functional capacity in "asymptomatic" older patients withprimary hyperparathyroidism: a randomized control trial. Ann Surg. 2010; 251(5):832-7.

228. Peng L, Liang J, Wang H, Song X, Rashid A, Gomez HF, Corley LJ, Abbruzzese JL, Fleming JB, EvansDB, Wang H. High levels of nucleolar expression of nucleolin are associated with better prognosiswith stage II pancreatic ductal adenocarcinoma. Clin Cancer Res. 2010; 16(14):3734-42.

229. Bose D, Tamm E, Liu J, Marcal L, Balachandran A, Bhosale P, Fleming JB, Lee JE, Evans DB, HwangRF. Multidisciplinary management strategy for incidental cystic lesions of the pancreas. J Am CollSurg. 2010; 211(2):205-15.

230. Abadeer RA, Fleming JB, Deavers MT, Rashid A, Evans DB, Wang H. Metastatic adult granulosa celltumor mimicking a benign pancreatic cyst. Ann Diagn Pathol. 2010; 14(6):457-60.

231. Liang JJ, Zhu S, Bruggeman R, Zaino RJ, Evans DB, Fleming JB, Gomez HF, Zander DS, Wang H. Highlevels of expression of human stromal cell-derived factor-1 are associated with worse prognosis inpatients with stage II pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2010;19(10):2598-604.

232. Silberfein EJ, Bao R, Lopez A, Grubbs EG, Lee JE, Evans DB, Peerrier ND. Reoperativeparathyroidectomy: location of missed glands based on a contemporary nomenclature system. ArchSurg. 2010; 145(11):1065-8.

233. Grubbs EG, Waguespack SG, Rich TA, Xing Y, Ying AK, Evans DB, Lee JE, Perrier ND. Do the recentAmerican Thyroid Association (ATA) Guidelines accurately guide the timing of prophylacticthyroidectomy in MEN2A? Surgery. 2010; 148(6):1302-9.

234. Song X, Wang H, Logsdon CD, Rashid A, Fleming JB, Abbruzzese JL, Gomez HF, Evans DB, Wang H.Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival inpancreatic ductal adenocarcinoma. Cancer. 2011 Feb 15;117(4):734-43. PMCID: PMC4403266

235. Moreno MA, Callender GG, Woodburn K, Edeiken-Monroe BS, Grubbs EG, Evans DB, Lee JE, PerrierND. Common locations of parathyroid adenomas. Ann Surg Oncol. 2011 Apr;18(4):1047-51.

236. Moreno MA, Callender GG, Woodburn K, Edeiken-Monroe BS, Grubbs EG, Evans DB, Lee JE, PerrierND. Common locations of parathyroid adenomas. Ann Surg Oncol. 2011; 18(4):1047-51.

237. Dickson PV, Jimenez C, Chisholm GB, Kennamer DL, Ng C, Grubbs EG, Evans DB, Lee JE, Perrier ND.Posterior retroperitoneoscopic adrenalectomy: a contemporary american experience. J Am Coll Surg.2011; 212(4):659-65.

238. Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz S, McConkey DJ, Evans DB, Gallick GE.ALDH Activity Selectively Defines an Enhanced Tumor-Initiating Cell Population Relative to CD133Expression in Human Pancreatic Adenocarcinoma. PLoS One. 2011; 6(6):e20636.

239. Katz MH, Wolff R, Crane CH, Varadhachary G, Javle M, Lin E, Evans DB, Lee JE, Fleming JB, PistersPW. Survival and Quality of Life of Patients with Resected Pancreatic Adenocarcinoma Treated withAdjuvant Interferon-Based Chemoradiation: A Phase II Trial. Ann Surg Oncol. 2011 June 24. [Epubahead of print].

240. Dickson PV, Alex GC, Grubbs EG, Ayala-Ramiez M, Jimenez C, Evans DB, Lee JE, Perrier ND. Posteriorretroperitoneoscopic adrenalectomy is a safe and effective alternative to transabdominal laparoscopicadrenalectomy for pheochromocytoma. Surgery. 2011; 150(3):452-8.

241. Estrella JS, Rashid A, Fleming JB, Katz MH, Lee JE, Wolf RA, Varadhachary GR, Pisters PW, AbdallaEK, Vauthey JN, Wang H, Gomez HF, Evans DB, Abbruzzese JL, Wang H. Post-therapy pathologic

27 / 41

stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvantchemoradiation. Cancer. 2011 Jul 6. [Epub ahead of print].

242. Wilson SD, Doffek KM, Wang TS, Krzywda EA, Evans DB, Yen TW. Primary hyperparathyroidism witha history of head and neck irradiation: the consequences of associated thyroid tumors. Surgery.2011;150(4):869-77.

243. Amin AL, Wang TS, Wade TJ, Quiroz FA, Hellman RS, Evans DB, Yen TW. Nonlocalizing imagingstudies for hyperparathyroidism: where to explore first? J Am Coll Surg. 2011;213(6):793-9.

244. Dickson PV, Rich TA, Xing Y, Cote GJ, Wang H, Perrier ND, Evans DB, Lee JE, Grubbs EG. Achievingeugastrinemia in MEN1 patients: Both duodenal inspection and formal lymph node dissection areimportant. Surgery. 2011;150(6):1143-52.

245. Evans DB. Papillary carcinoma of the thyroid: Balancing principles of oncology with emerging technology.Surgery. 2011;150(6):1015-22.

246. Wang J, Estrella JS, Peng L, Rashid A, Varadhachary GR, Wang H, Lee JE, Pisters PW, Vauthey JN, KatzMH, Gomez HF, Evans DB, Abbruzzese JL, Fleming JB, Wang H. Histologic tumor involvement ofsuperior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreaticadenocarcinoma treated with neoadjuvant chemoradiation. Cancer. 2012;118(15):3801-11.

247. Abbott DE, Cantor SB, Grubbs EG, Santora R, Gomez HF, Evans DB, Lee JE, Vu T, Perrier ND.Outcomes and econonmic analysis of routine preoperative 4-dimensional CT for surgical interventionin de novo primary hyperparathyroidism: does clinical benefit justify the cost? J Am Coll Surg.2012;214(4):629-37.

248. Aadam AA, Evans DB, Khan A, Oh Y, Dua K. Efficacy and safety of self-expandable metal stents forbiliary decompression in patients receiving neoadjuvant therapy for pancreatic cancer: a prospectivestudy. Gastrointest Endosc. 2012;76(1):67-75.

249. Mazeh H, Froyshteter AB, Wang TS, Amin, AL, Evans DB, Sippel RS, Chen H, Yen TW. Is previous samequadrant surgery a contraindication to laparoscopic adrenalectomy? Surgery. 2012;152(6):1211-7.

250. Wang TS, Evans DB, Fareau GG, Carroll T, Yen TW. Effect of prophylactic central compartment neckdissection on serum thyroglobulin and recommendations for adjuvant radioactive iodine in patientswith differentiated thyroid cancer. Ann Surg Oncol. 2012 Dec;19(13):4217-22.

251. Cayo AK, Yen TW, Misustin SM, Wall K, Wilson SD, Evans DB, Wang TS. Predicting the need forcalcium and calcitriol supplementation after total thyroidectomy: results of a prospective, randomizedstudy. Surgery. 2012 Dec;152(6):1059-67. PMCID: PMC4538326

252. Morris LF, Waguespack SG, Edeiken-Monroe BS, Lee JE, Rich TA, Ying AK, Warneke CL, Evans DB,Perrier ND, Grubbs EG. Ultrasonography should not guide the timing of thyroidectomy in pediatricpatients diagnosed with multiple endocrine neoplasia syndrome 2A through genetic screening. AnnSurg Oncol. 2013 Jan;20(1):53-9. PMCID: PMC3892987

253. Grubbs EG, Rich TA, Ng C, Bhosale PR, Jimenez C, Evans DB, Lee JE, Perrier ND. Long-term outcomesof surgical treatment for hereditary pheochromocytoma. J Am Coll Surg. 2013 Feb;216(2):280-9.

254. Grubbs EG, Rich TA, Ng C, Bhosale PR, Jimenez C, Evans DB, Lee JE, Perrier ND. Long-term outcomesof surgical treatment for hereditary pheochromocytoma. J Am Coll Surg. 2013 Feb;216(2):280-9.

255. Turaga KK, Tsai S, Wiebe LA, Evans DB, Gamblin TC. Novel multimodality treatment sequencing forextrahepatic (mid and distal) cholangiocarcinoma. Ann Surg Oncol. 2013 Apr;20(4):1230-9.

256. Wade TJ, Yen TW, Amin AL, Evans DB, Wilson SD, Wang TS. Focused parathyroidectomy withintraoperative parathyroid hormone monitoring in patients with lithium-associated primaryhyperparathyroidism. Surgery. 2013 May;153(5):718-22.

257. Christians KK, Riggle K, Keim R, Pappas S, Tsai S, Ritch P, Erickson B, Evans DB. Distal splenorenal andtemporary mesocaval shunting at the time of pancreatectomy for cancer: initial experience from theMedical College of Wisconsin. Surgery. 2013 Jul;154(1):123-31.

258. Leiker AJ, Yen TW, Eastwood DC, Doffek KM, Szabo A, Evans DB, Wang TS. Factors that influenceparathyroid hormone half-life: determining if new intraoperative criteria are needed. JAMA Surg. 2013Jul;148(7):602-6. PMCID: PMC4448959

259. Pilgrim CH, Tsai S, Evans DB, Christians KK. Mesocaval shunting: a novel technique to facilitate venousresection and reconstruction and enhance exposure of the superior mesenteric and celiac arteries duringpancreaticoduodenectomy. J Am Coll Surg. 2013 Sep;217(3):e17-20.

260. O'Connell K, Yen TW, Quiroz F, Evans DB, Wang TS. The utility of routine preoperative cervicalultrasonography in patients undergoing thyroidectomy for differentiated thyroid cancer. Surgery. 2013Oct;154(4):697-701; discussion 701-3.

28 / 41

261. Morris LF, Iupe IM, Edeiken-Monroe BS, Warneke CL, Hansen MO, Evans DB, Lee JE, Grubbs EG,Perrier ND. Pre-operative ultrasound identification of thyroiditis helps predict the need for thyroidhormone replacement after thyroid lobectomy. Endocr Pract. 2013 Nov-Dec;19(6):1015-20.

262. Miura JT, Evans DB, Pappas SG, Gamblin TC, Turaga KK. Borderline resectable/locally advancedpancreatic adenocarcinoma: improvements needed in population-based registries. Ann Surg Oncol.2013 Dec;20(13):4338-47.

263. Leiker AJ, Yen TW, Cheung K, Evans DB, Wang TS. Cost analysis of thyroid lobectomy andintraoperative frozen section versus total thyroidectomy in patients with a cytologic diagnosis of"suspicious for papillary thyroid cancer". Surgery. 2013 Dec;154(6):1307-13; discussion 1313-4.

264. Pilgrim CH, Tsai S, Tolat P, Patel P, Rilling W, Evans DB, Christians KK. Optimal Management of theSplenic Vein at the Time of Venous Resection for Pancreatic Cancer: Importance of the InferiorMesenteric Vein. J Gastrointest Surg 2013 Dec 18 [Epub ahead of print]. PMID:24347313.

265. Abbott DE, Tzeng CW, Merkow RP, Cantor SB, Chang GJ, Katz MH, Bentrem DJ, Bilimoria KY, CraneCH, Varadhachary GR, Abbruzzese JL, Wolff RA, Lee JE, Evans DB, Fleming JB. The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment ofpancreatic head adenocarcinoma. Ann Surg Oncol. 2013 Dec;20 Suppl 3:S500-8.

266. Pappas SG, Christians KK, Tolat PP, Mautz AP, Lal A, McElroy L, Gamblin TC, Turaga KK, Tsai S,Erickson B, Ritch P, Evans DB. Staging chest computed tomography and positron emissiontomography in patients with pancreatic adenocarcinoma: utility or futility? HPB (Oxford). 2014Jan;16(1):70-4. PMCID: PMC3892317

267. Tran Cao HS, Balachandran A, Wang H, Nogueras-González GM, Bailey CE, Lee JE, Pisters PW, EvansDB, Varadhachary G, Crane CH, Aloia TA, Vauthey JN, Fleming JB, Katz MH. Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable andborderline resectable pancreatic cancer. J Gastrointest Surg. 2014 Feb;18(2):269-78; discussion 278.PMCID: PMC4016045

268. Pilgrim CH, Tsai S, Tolat P, Patel P, Rilling W, Evans DB, Christians KK. Optimal management of thesplenic vein at the time of venous resection for pancreatic cancer: importance of the inferior mesentericvein. J Gastrointest Surg. 2014 May;18(5):917-21.

269. Tzeng CW, Tran Cao HS, Lee JE, Pisters PW, Varadhachary GR, Wolff RA, Abbruzzese JL, Crane CH, Evans DB, Wang H, Abbott DE, Vauthey JN, Aloia TA, Fleming JB, Katz MH. Treatment sequencingfor resectable pancreatic cancer: influence of early metastases and surgical complications onmultimodality therapy completion and survival. J Gastrointest Surg. 2014 Jan;18(1):16-24; discussion24-5.

270. Pilgrim CH, Evans DB, Christians KK. Reply: To PMID 23816382. J Am Coll Surg. 2014Feb;218(2):307-8.

271. White RR, Evans DB. Neoadjuvant chemotherapy for localized pancreatic cancer: too little or too long?Ann Surg Oncol. 2014 May;21(5):1508-9.

272. Bednarski BK, Habra MA, Phan A, Milton DR, Wood C, Vauthey N, Evans DB, Katz MH, Ng CS, PerrierND, Lee JE, Grubbs EG. Borderline resectable adrenal cortical carcinoma: a potential role forpreoperative chemotherapy. World J Surg. 2014 Jun;38(6):1318-27.

273. Roy I, Zimmerman NP, Mackinnon AC, Tsai S, Evans DB, Dwinell MB. CXCL12 chemokine expressionsuppresses human pancreatic cancer growth and metastasis. PLoS One. 2014;9(3):e90400. PMCID:PMC3942415

274. Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, EvansDB, George B. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatmentparadigm? Oncologist. 2014 Mar;19(3):266-74. PMCID: PMC3958454

275. Roy I, Evans DB, Dwinell MB. Chemokines and chemokine receptors: update on utility and challenges forthe clinician. Surgery. 2014 Jun;155(6):961-73. PMCID: PMC4390364

276. Christians KK, Pilgrim CH, Tsai S, Ritch P, George B, Erickson B, Tolat P, Evans DB. Arterial resection atthe time of pancreatectomy for cancer. Surgery. 2014 May;155(5):919-26.

277. Pilgrim CHC, Evans DB, Christians KK. Technical aspects of pancreatic surgery Handbook of Pancreaticand Hepatobiliary Surgery. 9 September 2014.

278. Kharofa J, Tsai S, Kelly T, Wood C, George B, Ritch P, Wiebe L, Christians K, Evans DB, Erickson B.Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer.Radiother Oncol. 2014 Oct;113(1):41-6. PMCID: PMC4530020

279. Carr AA, Yen TW, Fareau GG, Cayo AK, Misustin SM, Evans DB, Wang TS. A single parathyroid

29 / 41

hormone level obtained 4 hours after total thyroidectomy predicts the need for postoperative calciumsupplementation. J Am Coll Surg. 2014 Oct;219(4):757-64.

280. Krepline AN, Christians KK, Duelge K, Mahmoud A, Ritch P, George B, Erickson BA, Foley WD,Quebbeman EJ, Turaga KK, Johnston FM, Gamblin TC, Evans DB, Tsai S. Patency rates of portalvein/superior mesenteric vein reconstruction after pancreatectomy for pancreatic cancer. J GastrointestSurg. 2014 Nov;18(11):2016-25.

281. Miura JT, Jayakrishnan TT, Amini A, Johnston FM, Tsai S, Erickson B, Quebbeman EJ, Christians KK, Evans DB, Gamblin TC, Turaga KK. Defining the role of adjuvant external beam radiotherapy onresected adenocarcinoma of the ampulla of vater. J Gastrointest Surg. 2014 Nov;18(11):2003-8.

282. Evans DB, Tsai S. Volume-outcome in cancer surgery: why has the data not affected policy change? AnnSurg Oncol. 2014 Dec;21(13):4056-8.

283. Evans DB, Ritch PS, Erickson BA. Neoadjuvant therapy for localized pancreatic cancer: support isgrowing? Ann Surg. 2015 Jan;261(1):18-20.

284. Dy BM, Strajina V, Cayo AK, Richards ML, Farley DR, Grant CS, Harmsen WS, Evans DB, Grubbs EG,Bible KC, Young WF, Perrier ND, Que FG, Nagorney DM, Lee JE, Thompson GB. Surgical resectionof synchronously metastatic adrenocortical cancer. Ann Surg Oncol. 2015 Jan;22(1):146-51.

285. Jayakrishnan TT, Nadeem H, Groeschl RT, George B, Thomas JP, Ritch PS, Christians KK, Tsai S, EvansDB, Pappas SG, Gamblin TC, Turaga KK. Diagnostic laparoscopy should be performed beforedefinitive resection for pancreatic cancer: a financial argument. HPB (Oxford). 2015 Feb;17(2):131-9.PMCID: PMC4299387

286. Tsai S, George B, Christians KK, Evans DB. Neoadjuvant Chemotherapy and Radiochemotherapy: IsThere a Survival Advantage for Pancreatic Cancer Patients? Pancreatic Cancer, Cystic Neoplasms andEndocrine Tumors: Diagnosis and Management. 7 April 2015:103-119.

287. Christians KK, Evans DB. Additional support for neoadjuvant therapy in the management of pancreaticcancer. Ann Surg Oncol. 2015 Jun;22(6):1755-8.

288. Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F,Raue F, Frank-Raue K, Robinson B, Rosenthal MS, Santoro M, Schlumberger M, Shah M,Waguespack SG, American Thyroid Association Guidelines Task Force on Medullary ThyroidCarcinoma. Revised American Thyroid Association guidelines for the management of medullarythyroid carcinoma. Thyroid. 2015 Jun;25(6):567-610. PMCID: PMC4490627

289. Cooper AB, Slack R, Fogelman D, Holmes HM, Petzel M, Parker N, Balachandran A, Garg N, Ngo-HuangA, Varadhachary G, Evans DB, Lee JE, Aloia T, Conrad C, Vauthey JN, Fleming JB, Katz MH.Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for PotentiallyResectable Pancreatic Cancer. Ann Surg Oncol. 2015 Jul;22(7):2416-23.

290. O'Connell K, Yen TW, Shaker J, Wilson SD, Evans DB, Wang TS. Low 24-hour urine calcium levels inpatients with sporadic primary hyperparathyroidism: is further evaluation warranted prior toparathyroidectomy? Am J Surg. 2015 Jul;210(1):123-8.

291. Fathi A, Christians KK, George B, Ritch PS, Erickson BA, Tolat P, Johnston FM, Evans DB, Tsai S.Neoadjuvant therapy for localized pancreatic cancer: guiding principles. J Gastrointest Oncol. 2015Aug;6(4):418-29. PMCID: PMC4502155

292. Bagante F, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans DB, Hatzaras I, Shenoy R, Phay JE,Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC,Duh QY, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos KI, Levine EA, Poultsides GA, PawlikTM. Neutrophil-lymphocyte and platelet-lymphocyte ratio as predictors of disease specific survivalafter resection of adrenocortical carcinoma. J Surg Oncol. 2015 Aug;112(2):164-72. PMCID:PMC4962528

293. Roy I, McAllister DM, Gorse E, Dixon K, Piper CT, Zimmerman NP, Getschman AE, Tsai S, Engle DD, Evans DB, Volkman BF, Kalyanaraman B, Dwinell MB. Pancreatic Cancer Cell Migration andMetastasis Is Regulated by Chemokine-Biased Agonism and Bioenergetic Signaling. Cancer Res. 2015Sep 01;75(17):3529-42. PMCID: PMC4560104

294. Aldakkak M, Christians KK, Krepline AN, George B, Ritch PS, Erickson BA, Johnston FM, Evans DB,Tsai S. Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapyin patients with localized pancreatic cancer. HPB (Oxford). 2015 Oct;17(10):942-52. PMCID:PMC4571763

295. Marcal LP, Fox PS, Evans DB, Fleming JB, Varadhachary GR, Katz MH, Tamm EP. Analysis of free-formradiology dictations for completeness and clarity for pancreatic cancer staging. Abdom Imaging. 2015Oct;40(7):2391-7.

30 / 41

296. Glenn JA, Yen TW, Fareau GG, Carr AA, Evans DB, Wang TS. Institutional experience with lateral neckdissections for thyroid cancer. Surgery. 2015 Oct;158(4):972-8; discussion 978-80.

297. Evans DB, George B, Tsai S. Non-metastatic Pancreatic Cancer: Resectable, Borderline Resectable, andLocally Advanced-Definitions of Increasing Importance for the Optimal Delivery of MultimodalityTherapy. Ann Surg Oncol. 2015 Oct;22(11):3409-13.

298. Asare EA, Sturgeon C, Winchester DJ, Liu L, Palis B, Perrier ND, Evans DB, Winchester DP, Wang TS.Parathyroid Carcinoma: An Update on Treatment Outcomes and Prognostic Factors from the NationalCancer Data Base (NCDB). Ann Surg Oncol. 2015 Nov;22(12):3990-5.

299. Miura JT, Krepline AN, George B, Ritch PS, Erickson BA, Johnston FM, Oshima K, Christians KK, EvansDB, Tsai S. Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer.Surgery. 2015 Dec;158(6):1545-55.

300. Lai V, Yen TW, Rose BT, Fareau GG, Misustin SM, Evans DB, Wang TS. The Effect of Thyroiditis on theYield of Central Compartment Lymph Nodes in Patients with Papillary Thyroid Cancer. Ann SurgOncol. 2015 Dec;22(13):4181-6.

301. Margonis GA, Kim Y, Prescott JD, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans DB, Hatzaras I,Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, YoppAC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos KI, Levine EA,Poultsides GA, Pawlik TM. Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes. Ann Surg Oncol. 2016 Jan;23(1):134-41. PMCID: PMC4955567

302. Amini N, Margonis GA, Kim Y, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans DB, Hatzaras I,Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, YoppAC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos KI, Levine EA,Poultsides GA, Pawlik TM. Curative Resection of Adrenocortical Carcinoma: Rates and Patterns ofPostoperative Recurrence. Ann Surg Oncol. 2016 Jan;23(1):126-33. PMCID: PMC4962540

303. Ortiz DI, Findling JW, Carroll TB, Javorsky BR, Carr AA, Evans DB, Yen TW, Wang TS. Cosyntropinstimulation testing on postoperative day 1 allows for selective glucocorticoid replacement therapy afteradrenalectomy for hypercortisolism: Results of a novel, multidisciplinary institutional protocol.Surgery. 2016 Jan;159(1):259-65.

304. Berg RW, Yen TW, Evans DB, Hunt B, Quiroz FA, Wilson SD, Wang TS. Analysis of an institutionalprotocol for thyroid lobectomy: Utility of routine intraoperative frozen section and expedited(overnight) pathology. Surgery. 2016 Feb;159(2):512-7.

305. Margonis GA, Amini N, Kim Y, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans DB, Hatzaras I,Shenoy R, Phay JE, Keplinger K, Fields RC, Moses LE, Weber SM, Salem A, Sicklick JK, Gad S,Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos KI, Levine EA,Poultsides GA, Pawlik TM. Incidence of Perioperative Complications Following Resection ofAdrenocortical Carcinoma and Its Association with Long-Term Survival. World J Surg. 2016Mar;40(3):706-714. PMCID: PMC4957940

306. Christians KK, Heimler JW, George B, Ritch PS, Erickson BA, Johnston F, Tolat PP, Foley WD, EvansDB, Tsai S. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.Surgery. 2016 Mar;159(3):893-900.

307. Glenn JA, Kiernan CM, Yen TW, Solorzano CC, Carr AA, Evans DB, Wang TS. Management ofsuspected adrenal metastases at 2 academic medical centers. Am J Surg. 2016 Apr;211(4):664-70.

308. Kim Y, Margonis GA, Prescott JD, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans DB, Hatzaras I,Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem AI, Sicklick JK, Gad S, YoppAC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos KI, Levine EA,Poultsides GA, Pawlik TM. Nomograms to Predict Recurrence-Free and Overall Survival AfterCurative Resection of Adrenocortical Carcinoma. JAMA Surg. 2016 Apr;151(4):365-73. PMCID:PMC4967352

309. Glenn JA, Yen TW, Javorsky BR, Rose BG, Carr AA, Doffek KM, Evans DB, Wang TS. Associationbetween body mass index and multigland primary hyperparathyroidism. J Surg Res. 2016 May01;202(1):132-8.

310. Carr AA, Evans DB. Surgical management of parathyroid and adrenal glands in inherited medullary thyroidcarcinoma Medullary Thyroid Cancer. 20 July 2016:103-114.

311. Lai V, Yen TW, Doffek K, Carr AA, Carroll TB, Fareau GG, Evans DB, Wang TS. Delayed CalciumNormalization After Presumed Curative Parathyroidectomy is Not Associated with the Developmentof Persistent or Recurrent Primary Hyperparathyroidism. Ann Surg Oncol. 2016 07;23(7):2310-4.

312. Ortiz DI, Findling JW, Carroll TB, Javorsky BR, Carr AA, Evans DB, Yen TW, Wang TS. Response to

31 / 41

comments on: Cosyntropin stimulation testing on postoperative day 1 allows for selectiveglucocorticoid replacement therapy following adrenalectomy for hypercortisolism: Results of a novel,multidisciplinary institutional protocol. Surgery. 2016 07;160(1):249-250.

313. Younan G, Chimukangara M, Tsai S, Evans DB, Christians KK. Replaced gastroduodenal artery: Addedbenefit of the "artery first" approach during pancreaticoduodenectomy-A case report. Int J Surg CaseRep. 2016;23:93-7. PMCID: PMC4855750

314. Tsai S, Evans DB. Therapeutic Advances in Localized Pancreatic Cancer. JAMA Surg. 2016 0901;151(9):862-8.

315. Tsai S, Erickson BA, Dua K, Ritch PS, Tolat P, Evans DB. Evolution of the Management of ResectablePancreatic Cancer. J Oncol Pract. 2016 09;12(9):772-8.

316. Asare EA, Evans DB, Erickson BA, Aburajab M, Tolat P, Tsai S. Neoadjuvant treatment sequencing addsvalue to the care of patients with operable pancreatic cancer. J Surg Oncol. 2016 Sep;114(3):291-5.

317. Coan KE, Yen TWF, Carr AA, Bullock M, Colon-Franco JM, Evans DB, Wang TS. Intraoperative ex vivoparathyroid aspiration: A point-of-care test to confirm parathyroid tissue. Surgery. 201610;160(4):850-857.

318. de Geus SW, Evans DB, Bliss LA, Eskander MF, Smith JK, Wolff RA, Miksad RA, Weinstein MC, TsengJF. Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: A Markovdecision analysis. Eur J Surg Oncol. 2016 Oct;42(10):1552-60.

319. Krepline AN, Christians KK, George B, Ritch PS, Erickson BA, Tolat P, Evans DB, Tsai S. Venousthromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectablepancreatic cancer-Is it indicated? J Surg Oncol. 2016 Oct;114(5):581-586.

320. Tsai S, Christians KK, Ritch PS, George B, Khan AH, Erickson B, Evans DB. Multimodality Therapy inPatients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Importance ofLocoregional Therapies for a Systemic Disease. J Oncol Pract. 2016 10;12(10):915-923.

321. Younan G, Tsai S, Evans DB, Christians KK. Techniques of Vascular Resection and Reconstruction inPancreatic Cancer. Surg Clin North Am. 2016 Dec;96(6):1351-1370.

322. Rajamanickam ES, Christians KK, Aldakkak M, Krepline AN, Ritch PS, George B, Erickson BA, FoleyWD, Aburajab M, Evans DB, Tsai S. Poor Glycemic Control Is Associated with Failure to CompleteNeoadjuvant Therapy and Surgery in Patients with Localized Pancreatic Cancer. J Gastrointest Surg.2017 03;21(3):496-505.

323. La J, Wang TS, Hammad AY, Burgardt L, Doffek K, Carr AA, Shaker JL, Carroll TB, Evans DB, YenTW. Parathyroidectomy for primary hyperparathyroidism improves sleep quality: A prospective study.Surgery. 2017 01;161(1):25-34.

324. Cloyd JM, Katz MH, Prakash L, Varadhachary GR, Wolff RA, Shroff RT, Javle M, Fogelman D, OvermanM, Crane CH, Koay EJ, Das P, Krishnan S, Minsky BD, Lee JH, Bhutani MS, Weston B, Ross W,Bhosale P, Tamm EP, Wang H, Maitra A, Kim MP, Aloia TA, Vauthey JN, Fleming JB, AbbruzzeseJL, Pisters PW, Evans DB, Lee JE. Preoperative Therapy and Pancreatoduodenectomy for PancreaticDuctal Adenocarcinoma: a 25-Year Single-Institution Experience. J Gastrointest Surg. 201701;21(1):164-174.

325. Younan G, Evans DB, Christians KK. Cavernous transformation of the portal vein requiring temporarymesocaval shunt and internal jugular vein interposition graft Case-Based Lessons in the Managementof Complex Hepato-Pancreato-Biliary Surgery. 18 March 2017:375-383.

326. Carr AA, Yen TW, Wilson SD, Evans DB, Wang TS. Using parathyroid hormone spikes duringparathyroidectomy to guide intraoperative decision-making. J Surg Res. 2017 03;209:162-167.

327. Roy I, Boyle KA, Vonderhaar EP, Zimmerman NP, Gorse E, Mackinnon AC, Hwang RF, Franco-Barraza J,Cukierman E, Tsai S, Evans DB, Dwinell MB. Cancer cell chemokines direct chemotaxis of activatedstellate cells in pancreatic ductal adenocarcinoma. Lab Invest. 2017 03;97(3):302-317. PMCID:PMC5334280

328. Hammad AY, Yen TWF, Carr AA, Evans DB, Wang TS. Disparities in access to care and outcomes inpatients with adrenocortical carcinoma. J Surg Res. 2017 06 01;213:138-146.

329. Morris R, Yen TWF, Doffek K, Carr AA, Wilson SD, Evans DB, Wang TS. Concurrent endocrine andother surgical procedures: an institutional experience. J Surg Res. 2017 05 01;211:107-113.

330. Younan G, Tsai S, Evans DB, Christians KK. A Novel Reconstruction Technique DuringPancreaticoduodenectomy After Roux-En-Y Gastric Bypass: How I do It. J Gastrointest Surg. 201707;21(7):1186-1191. PMCID: PMC5486682

331. Barnes CA, Krepline AN, Aldakkak M, Clarke CN, Christians KK, Khan AH, Hunt BC, Ritch PS, GeorgeB, Hall WA, Erickson BA, Evans DB, Tsai S. Is Adjuvant Therapy Necessary for All Patients with

32 / 41

Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy? J Gastrointest Surg. 2017Nov;21(11):1793-1803.

332. Blitzer GC, Hall WA, Tsai S, Aldakkak M, Hellman RS, Evans DB, Christians KK, George B, Ritch PS,Erickson BA. Should functional renal scans be obtained prior to upper abdominal IMRT for pancreaticcancer? Pract Radiat Oncol. 2017 Nov - Dec;7(6):e449-e455.

333. Barnes CA, Krzywda E, Lahiff S, McDowell D, Christians KK, Knechtges P, Tolat P, Hohenwalter M, DuaK, Khan AH, Evans DB, Geurts J, Tsai S. Development of a high risk pancreatic screening clinicusing 3.0 T MRI. Fam Cancer. 2018 01;17(1):101-111.

334. Wang TS, Kline G, Yen TW, Yin Z, Liu Y, Rilling W, So B, Findling JW, Evans DB, Pasieka JL. A Multi-institutional Comparison of Adrenal Venous Sampling in Patients with Primary Aldosteronism:Caution Advised if Successful Bilateral Adrenal Vein Sampling is Not Achieved. World J Surg. 201802;42(2):466-472.

335. Bhalla M, Aldakkak M, Kulkarni NM, O'Connor SD, Griffin MO Jr, Christians KK, Evans DB, Tsai S,Tolat PP. Characterizing indeterminate liver lesions in patients with localized pancreatic cancer at thetime of diagnosis. Abdom Radiol (NY). 2018 02;43(2):351-363.

336. Tsai S, McOlash L, Palen K, Johnson B, Duris C, Yang Q, Dwinell MB, Hunt B, Evans DB, Gershan J,James MA. Development of primary human pancreatic cancer organoids, matched stromal andimmune cells and 3D tumor microenvironment models. BMC Cancer. 2018 03 27;18(1):335. PMCID:PMC5870823

337. Chatzizacharias NA, Tsai S, Griffin M, Tolat P, Ritch P, George B, Barnes C, Aldakkak M, Khan AH, HallW, Erickson B, Evans DB, Christians KK. Locally advanced pancreas cancer: Staging and goals oftherapy. Surgery. 2018 05;163(5):1053-1062.

338. Iczkowski KA, Evans DB, Suster SM. Adrenal oncocytic pheochromocytoma with functionality in aneurofibromatosis patient: A case report Human Pathology: Case Reports. June 2018;12:39-41.

339. Massimino M, Evans DB, Podda M, Spinelli C, Collini P, Pizzi N, Bleyer A. Thyroid cancer in adolescentsand young adults. Pediatr Blood Cancer. 2018 08;65(8):e27025.

340. Bhandari S, Abdul MKM, Hollabaugh W, Sharma K, Evans DB, Guda N. Decreased trend in hospitalmortality from pancreatic cancer despite increase in number of hospital admissions. PLoS One.2018;13(7):e0199909. PMCID: PMC6051597

341. Zhang J, Jiang J, Luo Y, Li X, Lu Z, Liu Y, Huang J, Hou Y, Pang Y, Sun MYF, Wang TS, Evans DB,Pacak K, Zhuang Z, Gao X. Molecular evaluation of a sporadic paraganglioma with concurrent IDH1and ATRX mutations. Endocrine. 2018 08;61(2):216-223. PMCID: PMC7461619

342. Hughes DT, Rosen JE, Evans DB, Grubbs E, Wang TS, Solórzano CC. Prophylactic Central CompartmentNeck Dissection in Papillary Thyroid Cancer and Effect on Locoregional Recurrence. Ann Surg Oncol.2018 Sep;25(9):2526-2534.

343. Tsai S, Christians KK, George B, Ritch PS, Dua K, Khan A, Mackinnon AC, Tolat P, Ahmad SA, HallWA, Erickson BA, Evans DB. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapyfor Localized Pancreatic Ductal Adenocarcinoma. Ann Surg. 2018 10;268(4):610-619.

344. Mazotas IG, Yen TWF, Park J, Liu Y, Eastwood DC, Carr AA, Evans DB, Wang TS. A postoperativeparathyroid hormone-based algorithm to reduce symptomatic hypocalcemia following completion/totalthyroidectomy: A retrospective analysis of 591 patients. Surgery. 2018 10;164(4):746-753.

345. Tsai S, George B, Wittmann D, Ritch PS, Krepline AN, Aldakkak M, Barnes CA, Christians KK, Dua K,Griffin M, Hagen C, Hall WA, Erickson BA, Evans DB. Importance of Normalization of CA19-9Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. Ann Surg. 202004;271(4):740-747.

346. Carr AA, Yen TWF, Ortiz DI, Hunt BC, Fareau G, Massey BL, Campbell BH, Doffek KL, Evans DB,Wang TS. Patients with Oncocytic Variant Papillary Thyroid Carcinoma Have a Similar Prognosis toMatched Classical Papillary Thyroid Carcinoma Controls. Thyroid. 2018 11;28(11):1462-1467.

347. Chavez MI, Tsai S, Clarke CN, Aldakkak M, Griffin MO, Khan AH, Ritch PS, Erickson BA, Evans DB,Christians KK. Distal splenorenal and mesocaval shunting at the time of pancreatectomy. Surgery.2019 02;165(2):298-306.

348. Barnes CA, Chavez MI, Tsai S, Aldakkak M, George B, Ritch PS, Dua K, Clarke CN, Tolat P, Hagen C,Hall WA, Erickson BA, Evans DB, Christians KK. Survival of patients with borderline resectablepancreatic cancer who received neoadjuvant therapy and surgery. Surgery. 2019 09;166(3):277-285.

349. Krepline AN, Bliss L, Geurts J, Akinola I, Christians KK, George B, Ritch PS, Hall WA, Erickson BA, Evans DB, Tsai S. Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Doesit Change Practice? J Gastrointest Surg. 2020 02;24(2):235-242.

33 / 41

350. Wei AC, Ou FS, Shi Q, Carrero X, O'Reilly EM, Meyerhardt J, Wolff RA, Kindler HL, Evans DB,Deshpande V, Misdraji J, Tamm E, Sahani D, Moore M, Newman E, Merchant N, Berlin J, Goff LW,Pisters P, Posner MC. Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy forResectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Ann Surg Oncol.2019 Dec;26(13):4489-4497. PMCID: PMC6868305

351. Jariwalla NR, Khan AH, Dua K, Christians KK, Clarke CN, Aldakkak M, George B, Tutton S, Rilling W,Erickson B, Evans DB, Tsai S. Management of Acute Cholecystitis during Neoadjuvant Therapy inPatients with Pancreatic Adenocarcinoma. Ann Surg Oncol. 2019 Dec;26(13):4515-4521.

352. Mazotas IG, Yen TWF, Doffek K, Shaker JL, Carr AA, Evans DB, Wang TS. Persistent/Recurrent PrimaryHyperparathyroidism: Does the Number of Abnormal Glands Play a Role? J Surg Res. 202002;246:335-341.

353. Coan KE, Yen TWF, Carr AA, Evans DB, Wang TS. Confirmation of Parathyroid Tissue: Are SurgeonsAware of New and Novel Techniques? J Surg Res. 2020 02;246:139-144.

354. Hsieh LB, Yen TWF, Dream S, Patel D, Evans DB, Wang TS. Perioperative Management and Outcomes ofHyperthyroid Patients Unable to Tolerate Antithyroid Drugs. World J Surg. 2020Nov;44(11):3770-3777.

355. Rowan DJ, Hartley CP, Aldakkak M, Christians KK, Evans DB, Tsai S, Hagen CE. Gross tumor size usingthe AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant treatedpancreatic ductal adenocarcinoma Annals of Diagnostic Pathology. June 2020;46.

356. Barnes CA, Aldakkak M, Clarke CN, Christians KK, Bucklan D, Holt M, Tolat P, Ritch PS, George B, HallWA, Erickson BA, Evans DB, Tsai S. Value of Pretreatment ¹⁸F-fluorodeoxyglucosePositron Emission Tomography in Patients With Localized Pancreatic Cancer Treated WithNeoadjuvant Therapy. Front Oncol. 2020;10:500. PMCID: PMC7180175

357. Wittmann D, Hall WA, Christians KK, Barnes CA, Jariwalla NR, Aldakkak M, Clarke CN, George B, RitchPS, Riese M, Khan AH, Kulkarni N, Evans J, Erickson BA, Evans DB, Tsai S. Impact of NeoadjuvantChemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. Front Oncol.2020;10:460. PMCID: PMC7175033

358. Muraki T, Reid MD, Pehlivanoglu B, Gonzalez RS, Sekhar A, Memis B, Xue Y, Cheng J, Jang KT, MittalP, Cardona K, Kooby DA, Maithel S, Sarmiento JM, El-Rayes B, Lomberk G, Urrutia RA, ChristiansK, Tsai S, Evans DB, Adsay V. Variant anatomy of the biliary system as a cause of pancreatic and peri-ampullary cancers. HPB (Oxford). 2020 12;22(12):1675-1685.

359. Geurts JL, Strong EA, Wang TS, Evans DB, Clarke CN. Screening guidelines and recommendations forpatients at high risk of developing endocrine cancers. J Surg Oncol. 2020 May;121(6):975-983.

360. Krepline AN, Geurts JL, Akinola I, Christians KK, Clarke CN, George B, Ritch PS, Khan AH, Hall WA,Erickson BA, Griffin MO, Evans DB, Tsai S. Detection of germline variants using expandedmultigene panels in patients with localized pancreatic cancer HPB. 2020.

361. Kandimalla R, Shimura T, Mallik S, Sonohara F, Tsai S, Evans DB, Kim SC, Baba H, Kodera Y, Von HoffD, Chen X, Goel A. Identification of Serum miRNA Signature and Establishment of a Nomogram forRisk Stratification in Patients With Pancreatic Ductal Adenocarcinoma. Ann Surg. 2020 May 08.PMCID: PMC7648727

362. Krepline AN, Geurts JL, Akinola I, Christians KK, Clarke CN, George B, Ritch PS, Khan AH, Hall WA,Erickson BA, Griffin MO, Evans DB, Tsai S. Detection of germline variants using expandedmultigene panels in patients with localized pancreatic cancer. HPB (Oxford). 202012;22(12):1745-1752.

363. Rowan DJ, Hartley CP, Aldakkak M, Christians KK, Evans DB, Tsai S, Hagen CE. Gross tumor size usingthe AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant treatedpancreatic ductal adenocarcinoma. Ann Diagn Pathol. 2020 Jun;46:151485.

364. Barnes CA, Aldakkak M, Christians KK, Clarke CN, Dua K, George B, Ritch PS, Kamgar M, Hall WA,Kulkarni N, Erickson BA, Evans DB, Tsai S. Radiographic patterns of first disease recurrence afterneoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreaticcancer Surgery (United States). 2020.

365. Taskin OC, Clarke CN, Erkan M, Tsai S, Evans DB, Adsay V. Pancreatic neuroendocrine neoplasms:current state and ongoing controversies on terminology, classification and prognostication. JGastrointest Oncol. 2020 Jun;11(3):548-558. PMCID: PMC7340800

366. Barnes CA, Aldakkak M, Christians KK, Clarke CN, Dua K, George B, Ritch PS, Kamgar M, Hall WA,Kulkarni N, Erickson BA, Evans DB, Tsai S. Radiographic patterns of first disease recurrence afterneoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic

34 / 41

cancer. Surgery. 2020 09;168(3):440-447. 367. Kim RY, Christians KK, Aldakkak M, Clarke CN, George B, Kamgar M, Khan AH, Kulkarni N, Hall WA,

Erickson BA, Evans DB, Tsai S. Total Neoadjuvant Therapy for Operable Pancreatic Cancer. AnnSurg Oncol. 2021 Apr;28(4):2246-2256.

368. Krepline AN, Geurts JL, George B, Kamgar M, Madhavan S, Erickson BA, Hall WA, Griffin MO, EvansDB, Tsai S, Kim RY. Cost-effectiveness analysis of universal germline testing for patients withpancreatic cancer. Surgery. 2021 03;169(3):629-635.

369. Mora J, Krepline AN, Aldakkak M, Christians KK, George B, Hall WA, Erickson BA, Kulkarni N, EvansDB, Tsai S. Adjuvant therapy rates and overall survival in patients with localized pancreatic cancerfrom high Area Deprivation Index neighborhoods. Am J Surg. 2021 07;222(1):10-17.

370. Ward EP, Evans DB, Tsai S. Ten-year experience in optimizing neoadjuvant therapy for localizedpancreatic cancer-Medical college of Wisconsin perspective. J Surg Oncol. 2021May;123(6):1405-1413.

371. Zimmermann MT, Mathison AJ, Stodola T, Evans DB, Abrudan JL, Demos W, Tschannen M, AldakkakM, Geurts J, Lomberk G, Tsai S, Urrutia R. Interpreting Sequence Variation in PDAC-PredisposingGenes Using a Multi-Tier Annotation Approach Performed at the Gene, Patient, and Cohort Level.Front Oncol. 2021;11:606820. PMCID: PMC7973372

372. O'Sullivan K, Yen TWF, Doffek K, Dream S, Mazotas I, Evans DB, Wang TS. An Institutional experiencewith primary hyperparathyroidism in the elderly over two decades. Am J Surg. 2021Sep;222(3):549-553.

373. Malangoni MA, Evans DB, Prinz RA, Hodin RA, Rege R, Harken AH. Tips for authors of surgicalmanuscripts from senior reviewers. Surgery. 2021 07;170(1):341-344.

374. Gao C, Wisniewski L, Liu Y, Staal B, Beddows I, Plenker D, Aldakkak M, Hall J, Barnett D, Gouda MK,Allen P, Drake R, Zureikat A, Huang Y, Evans D, Singhi A, Brand RE, Tuveson DA, Tsai S, HaabBB. Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA. ClinCancer Res. 2021 01 01;27(1):226-236. PMCID: PMC7785673

Books, Chapters, and Reviews1. Crichlow RW, Evans DB: Cancer in the male breast. In Ariel, IM, Cleary, JB, eds. Breast Cancer: Diagnosis

and Treatment. New York: McGraw-Hill, 1987, 516-28.2. Naitove A, Evans DB, Ihde JK: Fluid and electrolyte balance in the surgical patient. In Lawrence, P.F., ed.

Essentials of General Surgery. Baltimore: Williams and Wilkins, 1988, 48-69.3. Naitove A, Evans DB, Ihde JK: Fluid and electrolyte balance in the surgical patient. In Lawrence, P.F., ed.

Essentials of General Surgery, Second Edition. Baltimore: Williams and Wilkins, 1992, 61-81.4. Merrell RC, Evans DB. Pancreatic islet cell tumors. In Cameron JL, ed. Current Surgical Therapy - 4.

Missouri: Mosby-Year Book, Inc., 1992, 451-457.5. Rich T, Ochran TG, Boyer A, Ames F, Ota DM, Evans DB, Ajani, J. Electron beam intraoperative

radiotherapy at M.D. Anderson Cancer Center: Preliminary Results. 3rd International Symposium onIntraoperative Radiation Therapy. In Mitsuyuki A, Masaji T, eds. Intraoperative Radiation Therapy,New York: Pergamon Press, 1991, 81-83.

6. Ota DM, Evans DB, Mansfield PF. Placement of a feeding jejunostomy. In Ballantyne GH, Leahy PF, ModlinIM, eds. Laparoscopic Surgery. Philadelphia: W.B. Saunders Co., 1994, 467-472.

7. Evans DB. Pancreaticoduodenectomy. In Roh M, Ames FC, eds. Atlas of Advanced Surgical Oncology.London: Mosby - Year Book 1994, 4.2 - 4.45.

8. Evans DB. Adrenalectomy. In Roh M, Ames FC, eds. Atlas of Advanced Surgical Oncology. London: Mosby- Year Book 1994, 9.2 - 9.16.

9. Evans DB, Winchester DJ, Lee JE. Laparoscopic cholecystojejunostomy. In MacFadyen BV, Ponsky JL, eds.Operative Laparoscopy and Thoracoscopy. New York:Lippincott-Raven 1996, 343-358.

10. Merrell RC, Evans DB. Pancreatic polypeptide - producing and nonfunctioning islet cell tumors of thepancreas. In Berger HG, Warshaw AL, Buchler M, Carr-Locke D, Neoptolemos J, Russell C, Sarr M,eds. The Pancreas, Oxford: Blackwell Science Ltd. 1998, 1275-1283.

11. Evans DB, Lee JE, Pisters PWT. Pancreaticoduodenectomy (Whipple Operation) and total pancreatectomyfor cancer. In Nyhus LM, Baker RJ, Fischer JF, eds. Mastery of Surgery, Third Edition. Boston: Little,Brown and Co. 1997, 1233-1249.

12. Evans DB, Abbruzzese JL, Rich TA. Cancer of the pancreas. In DeVita VT, Hellman S, Rosenberg SA, eds.Cancer, Principles and Practice of Oncology, Fifth Edition. Philadelphia: J.B. Lippincott Co. 1997,

35 / 41

1054-1087.13. Evans DB, Burgess MA, Goepfert H, Gagel RF. Medullary thyroid cancer. In Bardin CW, ed. Current

Therapy in Endocrinology and Metabolism, Sixth Edition. St. Louis: Mosby-Year Book, Inc. 1997,127-132.

14. Evans DB, Lee JE, Pisters PWT. Resection of the superior mesenteric-portal vein confluence duringpancreaticoduodenectomy. In HanyuF, Takasaki K, eds. Pancreaticoduodenectomy. Tokyo: Springer-Verlag 1997, 215-225.

15. Evans DB, Abbruzzese JL. Management of cancer of the pancreas. In Meyers MA, ed. Neoplasms of theDigestive Tract: Imaging, Staging and Management. New York: Lippincott-Raven 1998, 471-477.

16. Pisters PWT, Lee JE, Evans DB. Standard forms of pancreatic resection. Reber HA, ed. Pancreatic CancerPathogenesis, Diagnosis, and Treatment. Totowa, New Jersey: Humana Press 1998, 181-200.

17. Evans DB, Lee JE, Charnsangavej C. Unusual pancreatic tumors. In Cameron JL, ed. Current SurgicalTherapy, Sixth Edition. Philadelphia: Mosby-Year Book, Inc. 1998, 527-532.

18. Fleming RYD, Evans DB, Lee JE. Adrenal glands. Miller TA, ed. Modern Surgical Care: PhysiologicFoundations, Second Edition. St. Louis: Quality Medical Publishing, Inc. 1998, 1144-1164.

19. Termuhlen PM, Evans DB, Willet CG. Intraoperative radiation therapy in pancreatic carcinoma. InGunderson LL, Willet CG, Harrison LB, Calvo FA, eds. Intraoperative Irradiation - Techniques andResults. Totowa, New Jersey: Humana Press, Inc. 1999, 201-222.

20. Evans DB, Wolff RA, Abbruzzese JL. Cancer of the pancreas. In Pollock RE, ed. UICC Manual of ClinicalOncology, Seventh Edition. New York, NY: John Wiley & Sons, Inc. 1999, 453-475.

21. Gagel RF, Evans DB, Lee JE. Multiple endocrine neoplasia. In Pinchera A, ed. Endocrinology andMetabolism. Milan, Italy: McGraw Hill 2001, 755-765.

22. Breslin TM, Pisters PWT, Lee JE, Abbruzzese JL, Evans DB. Exocrine neoplasms of the pancreas. In BlandKI, Daly JM, Karakousis CP, eds. Surgical Oncology, contemporary principles and practice. NewYork: McGraw-Hill 2001, 637-658.

23. Evans DB, Abbruzzese JL, Willett CG. Cancer of the pancreas. In DeVita VT, Hellman S, Rosenberg SA,eds. Cancer, Principles and Practice of Oncology, Sixth Edition. Philadelphia: Lippincott Williams &Wilkins 2001;1126-1161.

24. Evans DB, Lee JE, Pisters PWT. Pancreaticoduodenectomy (Whipple Operation) and total pancreatectomyfor cancer. In Baker RJ, Fischer JF, eds. Mastery of Surgery, Fourth Edition. Philadelphia: LippincottWilliams & Wilkins 2001;1299-1318.

25. Wolff RA, Abbruzzese JL, Evans DB. Neoplasms of the exocrine pancreas. In Holland JF, Frei E, Bast RC,Kufe DW, Pollock RE, Weichelbaum RR, eds. Cancer Medicine, Fifth Edition. Ontario: B.C. Decker,Inc. 2000, 1436-1464.

26. Evans DB, Wolff RA. Neoplasms of the ampulla of Vater. In Holland JF, Frei E, Bast RC, Kufe DW,Pollock RE, Weichelbaum RR, eds. Cancer Medicine, Fifth Edition. Ontario: B.C. Decker, Inc. 2000,1431-1435.

27. Jean ME, Evans DB. Pancreatic carcinoma. In Bland KI, ed. The Practice of General Surgery. Philadelphia:WB Saunders, Co. 2002,777-785.

28. Evans DB, Lee JE, Pisters PWT. Periampullary cancer. In Cameron JL, ed. Current Surgical Therapy,Seventh Edition. St. Louis: Mosby, Inc. 2001,558-567.

29. Kikumori T, Evans DB, Lee JE, Cote GJ, Gagel RF. Genetic abnormalities in multiple endocrine neoplasiatype 2. In Doherty GM, Skogseid B, eds. Surgical Endocrinology. Philadelphia: Lippincott Williamsand Wilkins. 2001,531-540.

30. Frederick WAI, Breslin TM, Pisters PWT, Evans DB. Neoadjuvant therapy for adenocarcinoma of thepancreas. In Cameron JL, ed. Atlas of Clinical Oncology: Pancreatic Cancer. Ontario: B. C. DeckerInc. 2001,133-151.

31. Wirfel KL, Evans DB, Lee JE, Goepfert H, Gagel RF: Multiple endocrine neoplasia syndromes. In MoltichME, ed. Challenging Cases in Endocrinology,. New Jersey, Humana Press. 2002,391-404.

32. Frederick WAI, Wolff RA, Crane CH, Lee JE, Pisters PWT, Evans DB. Preoperative (neoadjuvant) therapyfor resectable adenocarcinoma of the pancreas. In Evans DB, Pisters PWT, Abbruzzese JL, eds.Pancreatic Cancer. New York: Springer-Verlag, Inc. 2002,243-254.

33. Jean ME, Lowy AM, Chiao PJ, Evans DB. The molecular biology of pancreatic cancer. In Evans DB,Pisters PWT, Abbruzzese JL, eds. Pancreatic Cancer. New York: Springer-Verlag, Inc. 2002,15-28.

34. Evans DB, Erickson RA. Diagnosis and assessment of resectability for neoplasms of the pancreas andperiampullary region. In Evans DB (guest editor) vanHeerden JA, Farley DR, eds. Operative

36 / 41

Techniques in General Surgery. Philadelphia: W. B. Saunders, Co. 2001;3:5-16.35. Grau AM, Evans DB, Hoff AO, Lee JE. Carcinoma of the parathyroid glands. In Pellitteri PK, McCaffrey

TV, eds. Endocrine Surgery of the Head and Neck. New York: Delmar Learning. 2003,429-440.36. Evans DB, Wolff RA, Crane CH, Pisters PWT. Cancer of the Pancreas. In Pollock RE, ed. UICC Manual of

Clinical Oncology, Eighth Edition. New York, NY: John Wiley & Sons, Inc. 2004, 465-486.37. Crane CH, Evans DB, Wolff RA, Abbruzzese JL, Pisters PWT, Janjan NA. The pancreas. In Cox JD, Ang

KK, eds. Radiation Oncology: Rationale, Technique, Results, Eighth Edition. Philadelphia, PA.Elsevier Science. 2003, 465-480.

38. Wolff RA, Abbruzzese JL, Evans DB. Neoplasms of the exocrine pancreas. In Holland JF, Frei E, Bast RC,Kufe DW, Pollock RE, Weichelbaum RR, eds. Cancer Medicine, Sixth Edition. Ontario: B.C. Decker,Inc. 2003, 1585-1614.

39. Yen TWF, Wolff RA, Evans DB. Neoplasms of the ampulla of Vater. In Holland JF, Frei E, Bast RC, KufeDW, Pollock RE, Weichelbaum RR, eds. Cancer Medicine, Sixth Edition. Ontario: B.C. Decker, Inc.2003, 1615-1621.

40. Evans DB, Wolff RA, Crane CH, Pisters PWT. Combined modality treatment for pancreatic cancer. InDeVita VT, Hellman S, Rosenberg SA, eds. Progress in Oncology. Boston: Jones and Bartlett,2004:250-276.

41. Brana RH, Evans DB. Thyroid and adrenal cancer. In Fisch MJ, Bruera E, eds. Handbook of AdvancedCancer Care. Cambridge, U.K.: Cambridge University Press, 2003:294-299.

42. Smith DL, Evans DB. Therapeutic principles of gastrointestinal neoplasia: surgery. In Abbruzzese JL, EvansDB, Willett CG, Fenoglio-Preiser C. Gastrointestinal Oncology. New York: Oxford University Press,2004:80-87.

43. Jean ME, Lowy AM, Evans DB, Chiao PJ. Molecular biology of pancreatic adenocarcinoma. In AbbruzzeseJL, Evans DB, Willett CG, Fenoglio-Preiser C. Gastrointestinal Oncology. New York: OxfordUniversity Press, 2004:336-343.

44. Abdalla EK, Pisters PWT, Evans DB. Clinical aspects and management of pancreatic adenocarcinoma:management options: potentially resectable pancreatic cancer. In Abbruzzese JL, Evans DB, WillettCG, Fenoglio-Preiser C. Gastrointestinal Oncology. New York: Oxford University Press,2004:363-376.

45. Pisters PWT, Evans DB, Wolff RA, Crane C. Staging and therapeutic approaches for patients with localizedpotentially curable pancreatic adenocarcinoma. In Ajani JA, Curley SA, Janjan NA, Lynch PM.Gastrointestinal Cancer. New York: Springer, 2005:184-196.

46. Yen TWF, Abdalla EK, Pisters PWT, Evans DB. Pancreaticoduodenectomy. In: VonHoff DD, Evans DB,Hruban RH, eds. Pancreatic Cancer. Sudbury, MA: Jones and Bartlett Publishers, 2005:265-285.

47. Scoggins CR, Lee JE, Evans DB. Pancreaticoduodenectomy with en bloc vascular resection andreconstruction for localized carcinoma of the pancreas. In: VonHoff DD, Evans DB, Hruban RH, eds.Pancreatic Cancer. Sudbury, MA: Jones and Bartlett, 2005:321-334.

48. Kouvaraki MA, Shapiro SE, Lee JE, Evans DB. Pancreatic endocrine neoplasms in multiple endocrineneoplasia type 1. In: VonHoff DD, Evans DB, Hruban RH, eds. Pancreatic Cancer. Sudbury, MA:Jones and Bartlett Publishers, 2005:631-664.

49. Wolff RA, Crane CH, Li D, Abbruzzese JL, Evans DB. Neoplasms of the exocrine pancreas. In Kufe DW,Bast RC, Hait WN, Hong WK, Pollock RE, Weichelbaum RR, Holland JF, Frei E, eds. Holland-FreiCancer Medicine, Seventh Edition. Hamilton, Ontario: B.C. Decker, Inc., 2006:1331-1358.

50. Kouvaraki MA, Evans DB, Hoff AO, Lee JE. Adrenal glands. Miller TA, ed. Modern Surgical Care:Physiologic Foundations and Clinical applications, 3rd Edition. NY, NY: Informa Healthcare, Inc.2006:965-988.

51. Camp ER, Tamm EP, Gomez HF, Wang H, Evans DB. Unusual pancreatic tumors. In Yeo CJ, ed.Shackelford's Surgery of the Alimentary Tract, Sixth Edition. Philadelphia, PA: Saunders Elsevier,2007:1431-1439.

52. Evans DB, Lee JE, Tamm EP, Pisters PWT. Pancreaticoduodenectomy (Whipple Operation) and totalpancreatectomy for cancer. In Fischer JF, ed. Mastery of Surgery, Fifth Edition. Philadelphia:Lippincott Williams & Wilkins 2007:1299-1317.

53. Yen TWF, Evans DB. Resection for neoplasms of the pancreas (proximal resection). In Clavien PA, SarrMG, Fong Y. Atlas of Upper Gastrointestinal and Hepato-Pancreato-Biliary Surgery. BerlinHeidelberg: Springer-Verlag, 2007:763-780.

54. Phillips K, Fleming JB, Tamm EP, Evans DB. Unusual pancreatic tumors. In Cameron JL, ed. Current

37 / 41

Surgical Therapy, 9th Edition. Philadelphia: Mosby Elsevier. 2008:524-529.55. Amos KD, Kennamer DL, Charnsangavej C, Wang H, Evans DB. Surgical treatment of pancreatic

adenocarcinoma. In Pollock RE, ed. Advanced Therapy in Surgical Oncology. Hamilton, Ontario: B.C.Decker, Inc., 2008:165-176.

56. Yao JC, Gupta S, Vauthey JN, Evans DB. Management of nonfunctioning islet cell carcinoma of thepancreas. In Pollock RE, ed. Advanced Therapy in Surgical Oncology. Hamilton, Ontario: B.C.Decker, Inc., 2008:443-448.

57. Kouvaraki MA, Perrier ND, Rich TA, Lee JE, Evans DB. Surgical treatment of MEN 1. In Pollock RE, ed.Advanced Therapy in Surgical Oncology. Hamilton, Ontario: B.C. Decker, Inc., 2008:449-464.

58. Kouvaraki MA, Perrier ND, Shapiro SE, Lee JE, Evans DB. Surgical treatment of MEN 2. In Pollock RE,ed. Advanced Therapy in Surgical Oncology. Hamilton, Ontario: B.C. Decker, Inc., 2008:465-473.

59. Yao JC, Rindi G, Evans DB. Pancreatic endocrine tumors. In DeVita VT, Lawrence TS, Rosenberg SA, eds.Cancer, Principles and Practice of Oncology, 8th Edition. Philadelphia: Lippincott Williams & Wilkins2008;1702-1720.

60. Crane CH, Varadhachary GR, Evans DB, Wolff RA. The Pancreas. In Cox JD, Ang KK, eds. RadiationOncology: Rationale, Technique, Results, 9th Edition. Philadelphia: Mosby Elsevier 2010; 516-533.

61. Evans DB, Vauthey JN, Lee JE. Open adrenalectomy for cancer. In Duh QY, Clark OH, Kebebew E, eds.Atlas of Endocrine Surgical Techniques. Philadelphia: Saunders Elsevier 2010; 205-218.

62. Rich Ta, Jimenez C, Evans DB. Hereditary pheochromocytoma and multiple endocrine neoplasia type 2(MEN2). In Weiss RE, Refetoff S, eds. Genetic Diagnosis of Endocrine Disorders. London: Elsevier2010; 181-191.

63. Wolff RA, Crane CH, Li D, Evans DB. Neoplasms of the exocrine pancreas. In Hong WK, Bast RC, HaitWN, Kufe DW, Pollock RE, Weichelbaum RR, Holland JF, Frei E, eds. Holland-Frei CancerMedicine, Eighth Edition. Shelton, CT: B.C. Decker, Inc., 2010:1144-1171.

64. Yao JC, Rindi G, Evans DB. Pancreatic neuroendocrine tumors. In DeVita VT, Lawrence TS, RosenbergSA, eds. Cancer, Principles and Practice of Oncology, 9th Edition. Philadelphia: Lippincott Williams& Wilkins 2011; 1489-1502.

65. Lal A, Christians KK, Evans DB. Vascular reconstruction during the Whipple operation. In Cameron JL,Cameron AM, eds. Current Surgical Therapy, 10th Edition. Philadelphia: Elsevier Saunders.2011:429-434.

66. Greenup RA, Wang TS, Evans DB. Evaluation of other neuroendocrine tumors of the pancreas. In Sippel RSand Chen H, eds. The Handbook of Endocrine Surgery. Singapore: World Scientific Publishing Co.2012;397-404.

67. Evans DB, Christians KK, Foley WD. Pancreaticoduodenectomy (Whipple Operation) and totalpancreatectomy for cancer. In Fischer JF, ed. Mastery of Surgery, Sixth Edition. Philadelphia:Lippincott Williams & Wilkins 2012:1445-1465.

68. Tsai S, Mortenson MM, Wang H, Tamm EP, Evans DB. Unusual pancreatic tumors. In Yeo CJ, ed.Shackelford's Surgery of the Alimentary Tract, Seventh Edition. Philadelphia, PA: Elsevier-Saunders,2013:1268-1275.

69. Wang TS, Yen TWF, Evans DB. Parathyroid management in the MEN syndromes. In Randolph GW, ed.Surgery of the Thyroid and Parathyroid Glands, Second Edition. Philadelphia, PA: Elsevier-Saunders,2013:648-656.

70. Evans DB. Perspective on pancreatic neoplasms. In Zinner MJ and Ashley SW, eds. Maingot's AbdominalOperations, twelfth edition. McGraw-Hill Companies, Inc. 2013:1227-1232.

71. Yao JC, Evans DB. Pancreatic neuroendocrine tumors DeVita, Hellman, and Rosenberg's Cancer: Principles& Practice of Oncology: Tenth Edition. 7 January 2015.

72. Pilgrim CHC, Evans DB, Christians KK. Technical aspects of pancreatic surgery. In Zyromski NJ, ed.Handbook of Hepato-Pancreato-Biliary Surgery. Philadelphia, PA: Wolters Kluwer, 2015:76-88.

73. Tsai S, George B, Christians KK, Evans DB. Neoadjuvant chemotherapy and radiochemotherapy: is there asurvival advantage for pancreatic cancer patients. In Beger HG, Nakao A, Neoptolemos JP, Peng SY,Sarr MG, eds. Pancreatic Cancer, Cystic Neoplasms, and Endocrine Tumors: Diagnosis andManagement. Oxford: Wiley-Blackwell, 2015:103-119.

74. Amini A, Christians KK, Evans DB. Postpancreatectomy hemorrhage: early and late. In Pawlik TM, MaithelSK, Merchant NB, eds. Gastrointestinal Surgery: Management of Complex PerioperativeComplications. New York: Springer, 2015: 271-280.

75. Evans DB. Editorial on pancreatic surgery. In Nelson H, Hunt KK, Veeramachaneni N, et al. eds. Operative

38 / 41

Standards for Cancer Surgery. Philadelphia: Wolters Kluwer Health. 2015:268-271.76. Geurts J, Rich TA, Evans DB, Wang TS. Hereditary syndromes involving pheochromocytoma and

paraganglioma. In Weiss RE, ed. Genetic Diagnosis of Endocrine Disorders. London: Elsevier2016:222-234.

77. Grubbs EG, Massey BL, Evans DB, Wang TS. Medullary thyroid cancer. In Gullane P, Goldstein D, eds.Head and Neck Surgery volume of Sataloff’s Comprehensive Textbook of Otolaryngology.Philadelphia, PA: Jaypee Brothers Medical Publishers, 2016:253-264.

78. Carr AA, Evans DB. Surgical management of parathyroid and adrenal glands in inherited medullary thyroidcarcinoma. In Wang TS, Evans DB, eds. Medullary Thyroid Cancer. Switzerland: SpringerInternational Publishing, 2016:103-114.

79. Lai V, Evans DB, Wang TS. Central node dissection for thyroid cancer. In Carty SE, ed. Atlas of EndocrineSurgery. Philadelphia, PA: Jaypee Brothers Medical Publishers, 2017:49-58.

80. Younan G, Evans DB, Christians KK. Cavernous transformation of the portal vein requiring temporarymesocaval shunt and internal jugular vein interposition graft. In Pawlik TM, Weber S, Gamblin TC,eds. Case-based Lessons in the Management of Complex Hepato-Pancreato-Biliary Surgery.Charm,Switzerland: Springer, 2017:375-384.

81. Tsai S, Evans DB. Neoadjuvant and adjuvant therapy for localized pancreatic cancer. In Cameron JL,Cameron AM, eds. Current Surgical Therapy, 12th Edition. Philadelphia: Elsevier, 2017:559-564.

82. Wolff RA, Crane CH, Li D, Evans DB, Maitra A, Tsai S. Neoplasms of the exocrine pancreas. In Bast RC,Croce CM, Hait WN, Hong WK, Kufe DW, Piccart-Gebhart M, Pollock RE, Weichelbaum RR, WangH, Holland JF, Frei E, eds. Holland-Frei Cancer Medicine, 9th Edition. Hoboken, NJ: WileyBlackwell, 2017:1129-1150.

83. Amini A, Evans, DB, Christians KK. Pancreaticoduodenectomy for neuroendocrine tumors. In Howe JR, ed.Endocrine and Neuroendocrine Surgery. Berlin, Germany. Springer, 2017:225-244.

84. Evans DB, Tolat PP, Christians KK. Pancreaticoduodenectomy and total pancreatectomy for cancer Fischer'sMastery of Surgery, Seventh Edition. 1 January 2018;2:1552-1572.

85. Geurts J, Evans DB, Tsai S. Molecular genetics of pancreatic neoplasms and inherited pancreatic cancersyndromes. In Morita SY, Balch CM, Klimberg VS, Pawlik TM, Posner MC, Tanabe KK, eds.Textbook of Complex General Surgical Oncology. New York, NY: McGraw-Hill, 2018:1509-1514.

86. Appel BL, Tolat P, Oshima K, Evans DB, Tsai S. Clinical and pathologic staging for pancreatic cancer. InMorita SY, Balch CM, Klimberg VS, Pawlik TM, Posner MC, Tanabe KK, eds. Textbook of ComplexGeneral Surgical Oncology. New York, NY: McGraw-Hill, 2018:1601-1608.

87. Christians KK, Thomas J, Zechlinski JJ, Evans DB, Tsai S. Pancreatic neuroendocrine tumors (PNET). InMorita SY, Balch CM, Klimberg VS, Pawlik TM, Posner MC, Tanabe KK, eds. Textbook of ComplexGeneral Surgical Oncology. New York, NY: McGraw-Hill, 2018:1601-1608.

88. Hudak K, Johnston FM, Wang H, Tamm EP, Mortenson MM, Evans DB, Tsai S. Unusual pancreatictumors. In Morita SY, Balch CM, Klimberg VS, Pawlik TM, Posner MC, Tanabe KK, eds. Textbookof Complex General Surgical Oncology. New York, NY: McGrawj-Hill,2018:1629-1636.

89. Yao JC, Clarke CN, Evans DB. Pancreatic neuroendocrine tumors DeVita, Hellman, and Rosenberg'sCancer: Principles & Practice of Oncology. 16 November 2018:1353-1367.

90. Asare EA, Wang H, Tamm EP, Mortenson MM, Evans DB, Tsai S. Unusual pancreatic tumors. In Yeo CJ,ed. Shackelford's Surgery of the Alimentary Tract, 8th Edition. Philadelphia, PA: Elsevier-Saunders,2019:1172-1180.

91. Evans DB. Perspective on pancreatic neoplasms. In Zinner MJ, Ashley SW, and Hines OJ, eds. Maingot'sAbdominal Operations, 13th edition. New York: McGraw-Hill Companies, Inc. 2019:1375-1380.

Editorials, Letters to Editor, Other1. Evans DB, Robinson AM, Pettit RJ. Acute pancreatitis with a normal amylase Dig Dis Sci

1986;31(7):779-780.2. Evans DB, Curley SA. Use of EEA® Stapler in reconstruction after gastric resection. Surg Gynecol Obstet

1989;169:347.3. Evans DB, Curley SA. (Response) Use of EEA® Stapler in reconstruction after gastric resection. Surg

Gynecol Obstet 1990;170:442.4. Frazier ML, Brown N, Pathak S, Mackay B, Cleary K, Olive M, Byrd DR, Evans DB, Levin B. Human cell

line from an adenocarcinoma of the ampulla of Vater. In Vitro Cell Dev Biol 1992;28A:149-153.5. Ota DM, Evans DB. Feeding jejunostomy techniques. Surgery 1993;113 (5):598.

39 / 41

6. Tyler DS, Evans DB. Reoperative pancreaticoduodenectomy. Ann Surg 1995;221:121-122.7. Evans DB, Abbruzzese JL, Rich TA. Pancreatic cancer. Cancer Bulletin 1994;46:467-468.8. Evans DB. Radical reoperation for advanced pancreatic carcinoma: commentary. J Surg Oncol

1996;61:11-13.9. Rich TA, Janjan NA, Abbruzzese JL, Evans DB. (Response) Preoperative and postoperative chemoradiation

strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J ClinOncol 1997;15:3292-3293.

10. Lee JE, Evans DB, Sherman SI, Gagel RF. Evaluation of the incidental adrenal mass. Am J Med1997;103:249-250.

11. Evans DB, Abbruzzese JL. Chemoradiation for localized pancreatic cancer: another perspective. Ann SurgOncol 1999;6:4-7.

12. Pisters PWT, Evans DB, Leung DHY, Brennan MF. To the Editor. (Letter in response to: Henne-Bruns et al.World J Surg. 2000;24:595-602.) World J Surg 2001;25:533-34.

13. Pisters PWT, Evans DB. Commentary (Invited commentary on Katsaragakis, et al. J Surg Oncol2001;77:26-29). J Surg Oncol 2001;77:30.

14. Evans DB, Pisters PWT. Commentary: Preoperative chemoradiation therapy for pancreatic cancer. Surg ClinNorth Am 2001;81:709-713.

15. Pisters PWT, Evans DB. Endoscopic ultrasound in the diagnosis and staging of pancreatic cancer. Oncology2002;16:47-54.

16. Evans DB, Hess KR, Pisters PWT. EPAC-1 trial of adjuvant therapy for resectable adenocarcinoma of thepancreas. Ann Surg. 2002;236:694; discussion 694-6.

17. Pisters PWT, Lee JE, Vauthey JN, Evans DB. Comment on Sewnath et al. A meta-analysis on the efficacy ofpreoperative biliary drainage for tumors causing obstructive jaundice. Ann Surg 2003;237:594-95.

18. Evans DB, Pisters PWT. Novel applications of endo GIA linear staplers during pancreaticoduodenectomyand total pancreatectomy. Am J Surg 2003;185:606.

19. Evans DB, Lee JH, Crane CH. In response to comment on Mullen JT, et al. Pancreaticoduodenectomy afterplacement of endobiliary metal stents. J Gastrointest Surg. 2006;7:1096-7.

20. Evans DB, Lee JH, Crane CH. Reply. J Gastrointest Surg. 2006;10(7):1096-7.21. Evans DB. Reply.Gastroenterology. 2006:131(6);2022.22. Evans DB, Perrier ND. Invited Commentary: On "Posterior retroperitoneoscopic adrenalectomy-results of

560 procedures in 520 patients". Surgery. 2006:140(6);951-2.23. Evans DB, Shapiro SE, Cote GJ. Invited commentary: Medullary thyroid cancer: The importance of RET

testing. Surgery. 2007:141(1);96-9.24. Evans DB, Rich TA, Cote GJ. Invited commentary: Surgical Management of Familial Hyperparathyroidism.

Ann Surg Oncol. 2007;14(5):1525-7.25. Solorzano CC, Evans DB. Invited commentary: Same-day ultrasound guidance in reoperations for locally

recurrent papillary thyroid cancer. Surgery. 2007;142(6):973-975.26. Raut CP, Evans DB. Variability in Reporting Resection Margin Status in Pancreatic Cancer. Ann Surg.

2008;247(4):717-718.27. Evans DB, Crane CH, Charnsangavej C, Wolff RA. The added value of multidisciplinary care for patients

with pancreatic cancer. Ann Surg Oncol. 2008;15(8):2078-80.28. Pisters PWT, Evans DB. Cisplatin, fluorouracil, interferon-alpha, and radiation as adjuvant therapy for

resected pancreatic cancer: is there a future for this regimen and/or should we change our approach toresearch and treatment of patients with pancreatic cancer? Ann Surg. 2008;248(2):152-3.

29. Rich TA, Waguespack SG, Evans DB. Invited commentary: Premonitory symptoms preceding metastaticmedullary thyroid cancer in multiple endocrine neoplasia type 2B: An exploratory analysis. Surgery.2008;144(6):1052-3.

30. Phan AT, Yao JC, Evans DB. Invited commentary: Treatment options for metastatic neuroendocrine tumors.Surgery. 2008;144(6):895-8.

31. Christians K, Evans DB. Pancreaticoduodenectomy and vascular resection: persistent controversy andcurrent recommendations. Ann Surg Oncol. 2009;16(4):789-91.

32. Yen TW, Evans DB. Do Practice Patterns Reflect Practice Guidelines? Ann Surg Oncol. 2010(6):1478-80.33. Evans DB, Erickson BA, Ritch P. Borderline resectable pancreatic cancer: definitions and the importance of

multimodality therapy. Ann Surg Oncol. 2010;17(11):2803-5.34. Wang TS, Evans DB. The importance of a multidisciplinary approach to endocrine tumors. Surgery

2010;148(6):1311-2.

40 / 41

35. Evans DB, Wolff RA. Adjuvant therapy for pancreatic cancer: a logical strategy in search of progress. AnnSurg Oncol. 2011; 18(5):1224-8.

36. Perrier NDP, Evans DB. Population-level predictors of persistent hyperparathyroidism. Surgery.2011;150(6):1120-1.

37. Hodin R, Angelos P, Carty S, Chen H, Clark O, Doherty G, Duh QY, Evans DB, Heller K, Inabnet W,Kebebew E, Pasieka J, Perrier N, Sturgeon C. No need to abandon unilateral parathyroid surgery. J AmColl Surg. 2012;215(2):297.

38. Varadhachary GR, Evans DB. Rational study endpoint(s) for preoperative trials in pancreatic cancer:pathologic response rate, margin negative resection, overall survival or 'all of the above'? Ann SurgOncol. 2013 Nov;20(12):3712-4.

39. Pilgrim CH, Evans DB, Christians KK. Reply. J Am Coll Surg. 2014;218(2):307-8. PMID:24440074.40. White RR, Evans DB. Neoadjuvant Chemotherapy for Localized Pancreatic Cancer: Too Little or Too

Long? Ann Surg Oncol. 2014;21(5):1508-9. PMID:24452411.41. Evans DB, Tsai S. Volume-Outcome in Cancer Surgery: Why has the Data Not Affected Policy Change?

Ann Surg Oncol. 2014;21(13):4056-8. PMID:25239003.42. Christians KK, Evans DB. Additional Support for Neoadjuvant Therapy in the Management of Pancreatic

Cancer. Ann Surg Oncol. 2015;22(6):1755-8. PMID:25519932.43. Evans DB, Ritch PS, Erickson BA. Neoadjuvant therapy for localized pancreatic cancer: support is growing?

Ann Surg. 2015 Jan;261(1):18-20. 44. Evans DB, George B, Tsai S. Non-metastatic Pancreatic Cancer: Resectable, Borderline Resectable, and

Locally Advanced-Definitions of Increasing Importance for the Optimal Delivery of MultimodalityTherapy. Ann Surg Oncol. 2015;22(11):3409-13.

45. Wang TS, Evans DB. Commentary on: Occult lymph node metastasis and risk of regional recurrence inpapillary thyroid cancer after bilateral prophylactic central neck dissection: A multi-institutional study.Surgery. 2017 02;161(2):472-474.

46. Clarke CN, Evans DB. Editorial: Small, asymptomatic, nonfunctioning pancreatic neuroendocrine tumors:Observation becoming standard of care? Surgery. 2019 08;166(2):164-165.

47. Evans DB, Kamgar M, Tsai S. Goals of Treatment Sequencing for Localized Pancreatic Cancer. Ann SurgOncol. 2019 Nov;26(12):3815-3819.

48. Clarke CN, Evans DB. Treatment sequencing for pancreatic neuroendocrine tumors: daring to challenge thestatus quo. J Gastrointest Oncol. 2020 Jun;11(3):545-547. PMCID: PMC7340804

49. Evans DB. The Complexity of Neoadjuvant Therapy for Operable Pancreatic Cancer: Lessons Learned FromSWOG S1505. Ann Surg. 2020 09 01;272(3):487.

50. Kim RY, Evans DB, Christians KK. Locally advanced pancreatic cancer: staging, operability, and theimportance of multimodality therapy. Hepatobiliary Surg Nutr. 2020 Aug;9(4):497-500. PMCID:PMC7423551

51. Evans DB. Commentary: Surgery for locally advanced pancreatic cancer after neoadjuvant therapy. Surgery.2021 05;169(5):1032-1033.

Powered by TCPDF (www.tcpdf.org)

41 / 41